WO2017007658A1 - Combinaison à médiation immunitaire pour le traitement du cancer - Google Patents

Combinaison à médiation immunitaire pour le traitement du cancer Download PDF

Info

Publication number
WO2017007658A1
WO2017007658A1 PCT/US2016/040151 US2016040151W WO2017007658A1 WO 2017007658 A1 WO2017007658 A1 WO 2017007658A1 US 2016040151 W US2016040151 W US 2016040151W WO 2017007658 A1 WO2017007658 A1 WO 2017007658A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
phenyl
pyrimidin
amine
diazabicyclo
Prior art date
Application number
PCT/US2016/040151
Other languages
English (en)
Inventor
Esteban Masuda
Donald G. Payan
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of WO2017007658A1 publication Critical patent/WO2017007658A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present application concerns a combination comprising a JAK inhibitor and an immunooncology agent and a method for administering the combination.
  • Immunooncology research has indicated that tumors are recognized by the immune system. Tumor development can be controlled long term, or stopped entirely, by an immune system response. However, cancer progression is often accompanied by a suppression or reduction in the immune response. In many cases, this suppression or reduction is sufficient to prevent or substantially inhibit the immune system from producing an effective antitumor response.
  • the lack of an immune response was initially attributed to changes in the tumor cells that made them a poor target for an immune response attack. The lack of an effective immune response may be due, in part, to the ability of some tumors to subvert the normal immune response to their advantage.
  • Janus Kinases are a family of cytoplasmic protein tyrosine kinases including JAK1, JAK2, JAK3 and TYK2. JAK activation has been linked to promotion of abnormal cell proliferation in certain cancers.
  • Immunooncology agents for use herein include anti-CD137 agents, anti-CTLA-4 antibodies, anti-SLAMF7 agents, anti-KIR agents, checkpoint pathway inhibitors, for example PD-1 inhibitors, such as an anti-PD-1 antibody, and PD-L1 inhibitors, such as anti-PD-Ll antibodies, and LAG-3 inhibitors, such as anti-LAG-3 antibodies.
  • Additional immunooncology agents include enzyme inhibitors, including kinase inhibitors, such as PI3K inhibitors, indole dioxygenase (IDO) inhibitors, and tryptophan 2,3- dioxygenase (TDO) inhibitors.
  • enzyme inhibitors including kinase inhibitors, such as PI3K inhibitors, indole dioxygenase (IDO) inhibitors, and tryptophan 2,3- dioxygenase (TDO) inhibitors.
  • immunooncology agents may be selected from nivolumab, pembrolizumab, lambrolizumab, pidilizumab, elotuzumab (BMS-901608), BMS- 936559, BMS-986016, MPDL3280A, AMP-224, MEDI4736, ipilimumab, tremelimumab, lirilumab, urelumab, idelalisib, AZD8186, INCB40093, INCB50465, 1-methyltryptophan, indoximod, NSC 36398 (dihydroquercetin, taxifolin), NLG919, INCB024360 (epacodostat), F001287, or combinations thereof.
  • the JAK inhibitor has a formula I
  • ring A is aryl, heteroaryl or a fused ring system
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkenyl, cycloalkyl, cycloalkylalkyl,
  • each R 2 independently is H, alkyl, alkoxy, amide, cyano, nitro, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, -R 5 , -OR 6 , -N(R 6 )2, - C(0)OR 6 , or -C(0)N(R 6 )2, or two R 2 groups, taken together with the atom or atoms to which they are attached, combine to form h R 3 independently is halo, alkyl,
  • R 4 is aryl, X and Y independently are O, NH or N-alkyl;
  • R 5 is an N-heterocyclyl, wherein a nitrogen atom in the N-heterocyclyl is optionally substituted by a substituent selected from alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -R 8 -OR 6 , -R
  • a carbon atom in the N-heterocyclyl is optionally substituted by a substituent selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyl, cycloalkylalkenyl,
  • cycloalkylalkynyl heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -R 8 -OR 6 , -R 8 -C(0)R 6 ,
  • each R 6 and each R 7 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl,
  • X and Y independently are O, NH or N-alkyl; each R 2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, or sulfonamide, or two R 2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; m is 0, 1, 2, 3 or 4; R 3 is selected from halo, cyano or alkyl, with particular examples of R 3 including fluoro or methyl; and R 4 and R 10 independently are selected from H or alkyl.
  • ring A is phenyl.
  • the JAK inhibitor has a formula III
  • ring A is a six-membered aryl or a six-membered heteroaryl ring; n is 0, 1 or 2; and m is 0, 1, 2, 3 or 4.
  • Each R 2 when present, is independently selected from alkyl, halo, haloalkyl, cyano, nitro, -OR 6 , -N(R 6 ) 2 , -C(0)OR 6 or -C(0)N(R 6 ) 2 .
  • Each R 3 when present, is independently selected from alkyl, halo or haloalkyl.
  • R 4 is selected from aryl or heteroaryl. Generally, at least one of R 5 and a substituent on R 4 is a bridged N-heterocyclyl.
  • Certain disclosed embodiments concern a method for treating a subject comprising administering to the subject a JAK inhibitor and an immunooncology agent.
  • administering to the subject comprises administering to a subject having a cell proliferative disorder.
  • the cell proliferative disorder may be, for example, a cancer of the tongue, mouth, pharynx, esophagus, stomach, small intestine, colon, rectum, anus, liver, gallbladder, pancreas, larynx, lung, bronchus, breast, cervix, endometrium, ovary, vulva, vagina, prostate, testis, penis, urinary bladder, kidney, renal pelvis, ureter, eye, brain, thyroid, bones, joints, skin or combinations thereof.
  • the JAK inhibitor and the immunooncology agent may be administered substantially simultaneously, or alternatively, they may be administered sequentially, in any order.
  • the JAK inhibitor and the immunooncology agent are administered within a time period such that the subject experiences a beneficial overlapping effect from both the JAK inhibitor and the immunooncology agent.
  • the method may further comprise administering at least one or plural additional therapeutic agents to the subject.
  • the additional therapeutic agent may be administered simultaneously with the JAK inhibitor, simultaneously with the immunooncology agent, or simultaneously with both; substantially simultaneously with the JAK inhibitor, substantially simultaneously with the immunooncology agent, or substantially simultaneously with both the JAK inhibitor and the immunooncology agent; or the additional therapeutic agent may be administered within a time period where the beneficial effect of the additional therapeutic agent overlaps with the therapeutic benefit of the JAK inhibitor, the therapeutic benefit of the immunooncology agent, or the therapeutic benefits of both the JAK inhibitor and the immunooncology agent.
  • the additional therapeutic agent may be an analgesic, antibiotic, antibody, anticoagulant, anti-inflammatory agent, immunosuppressant, Guanylate cyclase-C receptor agonist, intestinal secretagogue, antiviral, anticancer, antifungal, or combination thereof.
  • kits comprising a combination of a JAK inhibitor and an immunooncology agent.
  • Disclosed embodiments of the present application concern a combination suitable for immunooncology therapy, and a method for treating a subject comprising administering the combination.
  • Certain embodiments concern a combination comprising a JAK inhibitor, or inhibitors, and an immunooncology agent, such as an immune response promoter.
  • the JAK inhibitors and immune response promotors, as well as embodiments of a method for administering each, are discussed in more detail below.
  • Substituted when used to modify a specified group or moiety, means that at least one, and perhaps two or more, hydrogen atoms of the specified group or moiety is independently replaced with the same or different substituent groups as defined below.
  • a group, moiety or substituent may be substituted or unsubstituted, unless expressly defined as either "unsubstituted” or “substituted.” Accordingly, any of the groups specified herein may be unsubstituted or substituted. In particular embodiments, the substituent may or may not be expressly defined as substituted, but is still contemplated to be optionally substituted. For example, an "alkyl” substituent may be unsubstituted or substituted, but an "unsubstituted alkyl” may not be substituted.
  • substituted refers to all subsequent modifiers in a term, for example in the term “substituted arylCi-salkyl,” substitution may occur on the “Ci-salkyl” portion, the “aryl” portion or both portions of the arylCi-salkyl group.
  • alkyl includes substituted cycloalkyl groups.
  • R 60 is Ci- 6 alkyl; each R 70 is independently for each occurrence hydrogen or R 60 ; each R 80 is independently for each occurrence R 70 or
  • each M + is a counter ion with a net single positive charge.
  • Each M + is
  • an alkali metal ion such as K + , Na + , Li + ; an ammonium ion, such as + N(R 60 )4; or an alkaline metal earth ion, such as [Ca 2+ ]o.5, [Mg 2+ ]o.5, or [Ba 2+ ]o.5 (a subscript "0.5" means, for example, that one of the counter ions for such divalent alkali earth ions can be an ionized form of a compound of the disclosure and the other a typical counter ion such as chloride, or two ionized compounds can serve as counter ions for such divalent alkali earth ions, or a doubly ionized compound can serve as the counter ion for such divalent alkali earth ions).
  • an alkali metal ion such as K + , Na + , Li +
  • an ammonium ion such as + N(R 60 )4
  • an alkaline metal earth ion such as [Ca
  • Substituent groups for replacing hydrogen atoms on unsaturated carbon atoms in groups containing unsaturated carbons are, unless otherwise specified, -R 60 , halo, -0 ⁇ M + , -OR 70 , -SR 70 , -S ⁇ M + , -N(R 80 ) 2 , perhaloalkyl, -CN, -OCN, -SCN, -NO, -N0 2 , -N 3 , -S0 2 R 70 , -S0 3 " M + , -SO3R 70 , -OS0 2 R 70 , -OS0 3 -M + , -OSO3R 70 , -P0 3 - 2 (M + ) 2 , -P0 3 2 M 2+ , -P(O)(OR 70 )O-M + , -P(O)(OR 70 ) 2 , -C(0)R 70 , -C(S)R
  • R 60 , R 70 , R 80 and M + are as previously defined, provided that in case of substituted alkene or alkyne, the substituents are not -0 ⁇ M + , -OR 70 , -SR 70 , or -S ⁇ M + .
  • Substituent groups for replacing hydrogen atoms on nitrogen atoms in groups containing such nitrogen atoms are, unless otherwise specified, -R 60 , -0 ⁇ M + , -OR 70 , -SR 70 , -S ⁇ M + , -N(R 80 )2, perhaloalkyl, -CN, -NO, -NO2, -S(0) 2 R 7 °, -S0 3 M + , -SO3R 70 , -OS(0) 2 R 7 °, -OS0 3 M + , -OSO3R 70 , -P0 3 2 (M + ) 2 , -P0 3 2 M 2+ , -P(O)(OR 70 )O M + , -P(O)(OR 70 )(OR 70 ), -C(0)R 70 , -C(S)R 70 , -C(NR 70 )R 70 , -CO2R 70 , -C(S)OR
  • -OC(S)OR 70 -NR 70 C(O)R 70 , -NR 70 C(S)R 70 , -NR 70 CO 2 R 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)N(R 80 ) 2 , -NR 70 C(NR 70 )R 70 and -NR 70 C(NR 70 )N(R 80 ) 2 , where R 60 , R 70 , R 80 and M + are as previously defined.
  • a group that is substituted has 1 substituent, 2 substituents, 3 substituents, or 4 substituents.
  • the nesting of such substituted substituents is limited to three, thereby preventing the formation of polymers.
  • the first (outermost) group can only be substituted with unsubstituted substituents.
  • aryl-3 can only be substituted with substituents that are not themselves substituted.
  • impermissible substitution patterns e.g., methyl substituted with 5 fluoro groups. Such impermissible substitution patterns are easily recognized by a person having ordinary skill in the art.
  • any of the groups referred to herein may be optionally substituted by at least one, possibly two or more, substituents as defined herein. That is, a substituted group has at least one, possible two or more, substitutable hydrogens replaced by a substituent or substitutents as defined herein, unless the context indicates otherwise or a particular structural formula precludes substitution.
  • compounds may exhibit the phenomena of tautomerism, conformational isomerism, geometric isomerism, and/or optical isomerism.
  • certain disclosed compounds can include one or more chiral centers and/or double bonds and as a consequence can exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers, diasteromers, and mixtures thereof, such as racemic mixtures.
  • certain disclosed compounds can exist in several tautomeric forms, including the enol form, the keto form, and mixtures thereof.
  • alkyl groups are defined by a subscript, either a fixed integer or a range of integers.
  • “Csalkyl” includes n- octyl, iso-octyl, 3-octynyl, cyclohexenylethyl, cyclohexylethyl, and the like; where the subscript “8” designates that all groups defined by this term have a fixed carbon number of eight.
  • the term "Ci-6alkyl” refers to alkyl groups having from one to six carbon atoms and, depending on any unsaturation, branches and/or rings, the requisite number of hydrogens.
  • Ci-6alkyl groups include methyl, ethyl, vinyl, propyl, isopropyl, butyl, s-butyl, i-butyl, isobutyl, isobutenyl, pentyl, pentynyl, hexyl, cyclohexyl, hexenyl, and the like.
  • alkyl residue having a specific number of carbons is named generically, all geometric isomers having that number of carbons are intended to be encompassed.
  • either "propyl” or "Csalkyl” each include n-propyl, opropyl, propenyl, propynyl, and isopropyl.
  • Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from three to thirteen carbon atoms. Examples of cycloalkyl groups include opropyl, obutyl, opentyl, norbornyl, norbornenyl, ohexenyl, adamantyl and the like. As mentioned, alkyl refers to alkanyl, alkenyl, and alkynyl residues (and
  • alkyl groups whether alone or part of another group, e.g.
  • -C(0)alkyl have from one to twenty carbons, that is Ci-2oalkyl, such as from one to fifteen carbons, from one to ten carbons, from one to eight carbons, from one to six carbons, or from one to four carbons.
  • the carbonyl of the -C(0)alkyl group is not included in the carbon count, since "alkyl” is designated generically.
  • the optional substitution includes “oxo” the carbon of any carbonyls formed by such "oxo" substitution are included in the carbon count since they were part of the original carbon count limitation.
  • optional substitution includes carbon- containing groups, e.g. -CH2CO2H, the two carbons in this group are not included in the Ci-2oalkyl carbon limitation.
  • C4 iocycloalkylalkyl means a cycloalkyl bonded to the parent structure via an alkylene, alkylidene or alkylidyne; in this example the group is limited to 10 carbons inclusive of the alkylene, alkylidene or alkylidyne subunit.
  • the "alkyl” portion of, e.g. "C7-i4arylalkyl” is meant to include alkylene, alkylidene or alkylidyne, unless stated otherwise, e.g. as in the terms “C 7 -i4arylalkylene” or "C6-ioaryl-CH 2 CH 2 -.”
  • Alkoxy refers to the group -O-alkyl, where alkyl is as defined herein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, i-butoxy, seobutoxy, n- pentoxy, cyclohexyloxy, cyclohexenyloxy, cyclopropylmethyloxy, and the like.
  • Acyl refers to the groups -C(0)H, -C(0)alkyl, -C(0)aryl and -C(0)heterocyclyl.
  • Amide refers to the group -C(0)NH 2 or -N(H)acyl.
  • Amino refers to the group -NH2.
  • Aryl refers to a monovalent aromatic carbocyclic group of, unless specified otherwise, from 6 to 15 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-l,4-benzoxazin-3(4H)-one-7-yl, 9,10-dihydrophenanthrenyl, indanyl, tetralinyl, and fluorenyl and the like), provided that the point of attachment is through an atom of an aromatic portion of the aryl group and the aromatic portion at the point of attachment contains only carbons in the aromatic ring.
  • Aryl group are monocyclic, bicyclic, tricyclic or tetracyclic. Unless otherwise stated, an aryl group may be substituted or unsubstituted.
  • Arylalkyl refers to a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne moiety. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. When specified as “optionally substituted,” both the aryl, and the corresponding alkylene, alkylidene, or alkylidyne portion of an arylalkyl group can be optionally substituted.
  • Cv iiarylalkyl refers to an arylalkyl limited to a total of eleven carbons, e.g., a phenylethyl, a phenylvinyl, a phenylpentyl and a naphthylmethyl are all examples of a "C7-11 arylalkyl” group.
  • Arylene refers to an aryl that has at least two groups attached thereto.
  • phenylene refers to a divalent phenyl ring moiety.
  • a phenylene can have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto.
  • Aryloxy refers to the group -O-aryl, where aryl is as defined herein, including, by way of example, phenoxy, naphthoxy, and the like.
  • Carboxyl refers to -CO2H or salts thereof.
  • Carboxyl ester or “carboxy ester” or “ester” refers to the group -CC alkyl, -CC aryl or -CC heterocyclyl.
  • Carbonate refers to the group -OC0 2 alkyl, -OC0 2 aryl or -OC0 2 heterocyclyl.
  • Combination refers to two or more components that are administered such that the effective time period of the first component overlaps with the effective time period of the second and subsequent components.
  • a combination may be a composition comprising the components, or it may be two or more individual components administered substantially simultaneously, or sequentially in any order.
  • Halo or halogen refers to fluoro, chloro, bromo or iodo.
  • Haloalkyl and haloaryl refer generically to alkyl and aryl moieties that are substituted with one or more halogens, respectively.
  • dihaloaryl alkyl and aryl moieties that are substituted with one or more halogens, respectively.
  • trihaloaryl etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is a dihaloaryl group.
  • Haloalkyloxy refers to the group -O-alkyl, where alkyl is as defined herein, and further, alkyl is substituted with one or more halogens.
  • a haloC 1-3 alky loxy” group includes -OCF3, -OCF 2 H, -OCHF2, -OCH 2 CH 2 Br, -OCH 2 CH 2 CH 2 I, -OC(CH 3 ) 2 Br, -0CH 2 C1 and the like.
  • Heteroalkyl refers to an alkyl where one or more, but not all, carbons are replaced with a heteroatom.
  • a heteroalkyl group has either linear or branched geometry.
  • a “2 - 6 membered heteroalkyl” is a group that can contain no more than 5 carbon atoms, because at least one of the maximum 6 atoms must be a heteroatom, and the group is linear or branched.
  • a heteroalkyl group always starts with a carbon atom, that is, although a heteroalkyl may contain one or more heteroatoms, the point of attachment to the parent molecule is not a heteroatom.
  • a 2-6 membered heteroalkyl group includes, for example, - CH 2 XCH 3 , -CH 2 CH 2 XCH 3 , -CH 2 CH 2 XCH 2 CH 3 , -C(CH 2 ) 2 XCH 2 CH 3 and the like, where X is O, NH, NCi-6alkyl and S(0)o- 2 , for example. Unless otherwise stated, a heteroalkyl group may be substituted or unsubstituted.
  • Heteroaryl refers to an aromatic group having from 1 to 10 annular carbon atoms and 1 to 4 annular heteroatoms.
  • a heteroaryl moiety may have from 5 to 14 total annular atoms, such as from 5 to 12 annular atoms, from 5 to 10 annular atoms, from 5 to 8 annular atoms, or 5 or 6 annular atoms.
  • Heteroaryl groups have at least one aromatic ring component, but heteroaryls can be fully unsaturated or partially unsaturated. If any aromatic ring in the group has a heteroatom, then the group is a heteroaryl, even, for example, if other aromatic rings in the group have no heteroatoms. For example, 2H-pyrido[3,2-b][l,4]oxazin-3(4H)-one-7-yl, indolyl and
  • benzimidazolyl are "heteroaryls.”
  • Heteroaryl groups can have a single ring (e.g., pyridinyl, imidazolyl or furyl) or multiple condensed rings (e.g., indolizinyl, quinolinyl, benzimidazolyl or benzothienyl), where the condensed rings may or may not be aromatic and/or contain a heteroatom, provided that the point of attachment to the parent molecule is through an atom of the aromatic portion of the heteroaryl group.
  • the nitrogen and/or sulfur ring atom(s) of the heteroaryl group are optionally oxidized to provide for the N-oxide (N ⁇ 0), sulfinyl, or sulfonyl moieties.
  • Compounds described herein containing phosphorous, in a heterocyclic ring or not, include the oxidized forms of phosphorous.
  • Heteroaryl groups are monocyclic, bicyclic, tricyclic or tetracyclic. Unless otherwise stated, a heteroaryl group may be substituted or unsubstituted.
  • Heteroarylene generically refers to any heteroaryl that has at least two groups attached thereto.
  • pyridylene refers to a divalent pyridyl ring moiety. A pyridylene, thus can have more than two groups attached, but is defined by a minimum of two non- hydrogen groups attached thereto.
  • Heteroaryloxy refers to -O-heteroaryl.
  • Heteroatom refers to O, S, N, or P.
  • Heterocyclyl in the broadest sense includes aromatic and non-aromatic ring systems and more specifically refers to a stable three- to fifteen-membered ring moiety that consists of carbon atoms and from one to five heteroatoms.
  • a heterocyclyl moiety is a three- to twelve-membered ring moiety, a three- to ten-membered ring moiety, a three to eight-membered ring moiety, or a three to six-membered ring moiety.
  • the heterocyclyl moiety can be a monocyclic, bicyclic or tricyclic ring system, which can include fused or bridged ring systems as well as spirocyclic systems; and the nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl moiety can be optionally oxidized to various oxidation states.
  • the group -S(0)o- 2 - refers to -S- (sulfide), -S(O)- (sulfoxide), and -SO2- (sulfone) linkages.
  • annular nitrogens are meant to include their corresponding N-oxide form, although not explicitly defined as such in a particular example.
  • annular nitrogen atoms can be optionally quaternized.
  • Heterocycle includes heteroaryl and heteroalicyclyl, that is a heterocyclic ring can be partially or fully saturated or aromatic.
  • heterocyclylalkyl includes heteroalicyclylalkyls and
  • heteroarylalkyls Unless otherwise stated, a heterocyclyl group may be substituted or unsubstituted. Examples of heterocyclyl moieties include, but are not limited to, azetidinyl, acridinyl,
  • benzodioxolyl benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl,
  • Heterocyclylalkyl refers to a heterocyclyl group linked to the parent structure via, e.g. , an alkylene linker, for example (tetrahydrofuran-3-yl)methyl- or (pyridin-4-yl)methyl
  • Heterocyclyloxy refers to the group -O-heterocycyl.
  • Hydroalkyl refers to a hydroxy-substituted alkyl group, e.g. , -(CH2) x OH.
  • Immunooncology agent refers to a compound that promotes a body's immune response against cancer. Certain cancer cells act to inhibit an immune response against that cell, such as by inhibiting a T cell response against the cell. Immunooncology agents counteract the inhibition of the immune response. Immunooncology agents include, but are not limited to, anti-PD-1 antibodies, anti-PD-Ll antibodies, PI3K inhibitors, indole dioxygenase inhibitors and combinations thereof.
  • JAK inhibitor refers to a compound that inhibits at least one member of the Janus kinase family.
  • the Janus kinase (JAK) family is a recognized family of non-receptor tyrosine kinases. Mammals have four members of this family, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2).
  • Phosphorylated JAK kinases bind various STAT (Signal Transducer and Activator of
  • STAT proteins which are DNA binding proteins activated by
  • JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses. Studies suggest that JAK3 associates with the common gamma (yc) chain of the various cytokine receptors. JAK3 in particular selectively binds to receptors and is part of the cytokine signaling pathway for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21.
  • JAK1 interacts with, among others, the receptors for cytokines IL-2, IL-4, IL-7, IL-9, IL-13 and IL-21
  • JAK2 interacts with, among others, the receptors for IL-9, IL-13 and TNF-oc.
  • Methods for determining JAK inhibition are well known in the art and can be performed, for example, using kits or services commercially available from Ambit Biosciences, Invitrogen and others.
  • JAK inhibitors described herein have an IC50 for at least one member of the JAK family of less than about 10 ⁇ , such as less than 5 ⁇ , such as up to about 1 ⁇ or less than about 100 nM.
  • Methodabolite refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, "The Pharmacological Basis of Therapeutics” 12 th Ed., Pergamon Press, Gilman et al. (eds), 1990 which is herein incorporated by reference).
  • the metabolite of a compound described herein or its salt can itself be a biologically active compound in the body.
  • metabolite is meant to encompass those compounds not contemplated to have lost a progroup, but rather all other compounds that are formed in vivo upon administration of a compound of the disclosure which retain the biological activities described herein.
  • one aspect disclosed compounds specifically contemplated herein is a metabolite of a compound described herein.
  • a biologically active metabolite is discovered serendipitously, that is, no prodrug design per se was undertaken.
  • biologically active compounds inherently formed as a result of practicing methods of the disclosure are contemplated and disclosed herein.
  • Niro refers to the group -NO2.
  • Optional or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not.
  • One of ordinary skill in the art would understand that, with respect to any molecule that may optionally have one or more substituents, only synthetically feasible compounds are meant to be included.
  • “Optionally substituted” refers to all subsequent modifiers in a term, for example in the term “optionally substituted arylCi-salkyl,” optional substitution may occur on both the "Ci-salkyl” portion and the "aryl” portion of the arylCi-salkyl group.
  • optionally substituted alkyl includes optionally substituted cycloalkyl groups.
  • substituted when used to modify a specified group or moiety, means that one or more hydrogen atoms of the specified group or moiety are each, independently of one another, replaced with the same or different substituent groups as defined herein.
  • the phrase “optionally substituted by a substituent selected from” is meant to encompass when the group is substituted with one or more of the moieties listed after the phrase, and when it is not so substituted.
  • Oxy refers to -O- moiety (also designated as— * ⁇ 0), that is, a single bond oxygen moiety.
  • N-oxides are nitrogens bearing an oxy moiety.
  • Patient or Subject refers to mammals and other animals, particularly humans. Thus the disclosed embodiments of the method are applicable to both human therapy and veterinary applications.
  • the patient or subject is a mammal.
  • the patient or subject is a human.
  • Perhalo as a modifier means that the group so modified has all its available hydrogens replaced with halogens.
  • An example would be "perhaloalkyl.” Perhaloalkyls include -CF3, - CF2CF3, perchloroethyl and the like.
  • “Pharmaceutically acceptable salt” refers to pharmaceutically acceptable salts of a compound, which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic
  • salts of organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate, and the like.
  • Pharmaceutically acceptable acid addition salts are those salts that retain the biological effectiveness of the free bases while formed by acid partners that are not biologically or otherwise undesirable, e.g., inorganic acids such as
  • hydrochloric acid hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, e
  • Pharmaceutically acceptable base addition salts include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from
  • organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2- dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine,
  • methylglucamine methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.
  • exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
  • suitable salts include citrate salts and xinafoate salts.
  • “Pharmaceutically effective amount” and “therapeutically effective amount” refer to an amount of a compound or combination sufficient to treat a specified disorder or disease or one or more of its symptoms and/or to prevent the occurrence of the disease or disorder.
  • the amount of a compound or combination which constitutes a “therapeutically effective amount” will vary depending on the compound or combination, the disease state and its severity, the age of the subject to be treated, and the like. The therapeutically effective amount can be determined routinely by one of ordinary skill in the art.
  • Prodrug refers to compounds that are transformed in vivo to yield the parent compound, for example, by hydrolysis in the gut or enzymatic conversion in blood.
  • the prodrug includes at least one functional group masked with a progroup or promoiety, which may be cleaved under conditions of use.
  • Common examples include, but are not limited to, ester and amide forms of a compound having an active form bearing a carboxylic acid moiety.
  • Examples of pharmaceutically acceptable esters of the compounds of this disclosure include, but are not limited to, alkyl esters (for example with between about one and about six carbons) where the alkyl group is a straight or branched chain, and phosphates.
  • Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl.
  • Examples of pharmaceutically acceptable amides of the compounds of this disclosure include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons).
  • Amides and esters of the compounds of the present disclosure can be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.
  • Additional Therapeutic as used herein concerns any additional compound, drug, or formulation that can be used with disclosed embodiments of the combination described here.
  • solvent refers to a complex formed by combination of solvent molecules with molecules or ions of the solute.
  • the solvent can be an organic compound, an inorganic compound, or a mixture of both.
  • solvents include, but are not limited to, methanol, N,N- dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and water.
  • the compounds described herein can exist in unsolvated as well as solvated forms with solvents, pharmaceutically acceptable or not, such as water, ethanol, and the like. Solvated forms of the presently disclosed compounds are contemplated herein and are encompassed by the disclosure, at least in generic terms.
  • Stereoisomer and “stereoisomers” refer to compounds that have the same atomic connectivity but different atomic arrangement in space. Stereoisomers include cis-trans isomers, E and Z isomers, enantiomers and diastereomers. Compounds of the disclosure, or their
  • pharmaceutically acceptable salts can contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry, as (R)- or (5)- or, as (D)- or (L)- for amino acids.
  • the present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optically active (+) and (-), (R)- and (5)-, or (D)- and (L)- isomers can be prepared using chiral synthons, chiral reagents, or resolved using conventional techniques, such as by: formation of diastereoisomeric salts or complexes which can be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which can be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas- liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form.
  • specific enantiomer can be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting on enantiomer to the other by asymmetric transformation.
  • the major component enantiomer can be further enriched (with concomitant loss in yield) by recrystallization.
  • Sulfonamide refers to the group -SO2NH2, -N(H)S0 2 H, -N(H)S0 2 alkyl, -N(H)S0 2 aryl, or -N(H)S02heterocyclyl.
  • Sulfonyl refers to the group -SO2H, -S0 2 alkyl, -S0 2 aryl, or -S0 2 heterocyclyl.
  • Sulfanyl refers to the group: -SH, -S-alkyl, -S-aryl, or -S-heterocyclyl.
  • Sulfinyl refers to the group: -S(0)H, -S(0)alkyl, -S(0)aryl or -S(0)heterocyclyl.
  • pyrazoles imidazoles, benzimidazoles, triazoles, and tetrazoles.
  • Treating covers the treatment of the disease, disorder or condition of interest in a mammal, preferably a human, having the disease, disorder or condition of interest, and includes: (i) preventing the disease, disorder or condition from occurring in a mammal, in particular, when such mammal is predisposed to the condition but has not yet been diagnosed as having it;
  • the terms "disease,” “disorder” and “condition” can be used interchangeably or can be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease or disorder but only as an undesirable condition or syndrome, where a more or less specific set of symptoms have been identified by clinicians.
  • the present disclosure concerns the use of particular compounds in combination with immunooncology agents for treating and/or preventing certain diseases or disorders, such as cell proliferative disorders including various cancers.
  • Embodiments of the compounds for use in the disclosed combinations are JAK inhibitors.
  • the JAK inhibitor com rises a compound having a formula I
  • ring A is aryl, heteroaryl or a fused ring system.
  • R 1 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, aryl, aralkyl, aralkenyl, aralkynyl,
  • Each R 2 independently is H, alkyl, alkoxy, amide, cyano, nitro, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, -R 5 , -OR 6 , -N(R 6 )2, -C(0)OR 6 , or -
  • R 3 independently is halo, alkyl, cyano or haloalkyl.
  • R 4 is aryl, heteroaryl or
  • X and Y independently are O, NH or N-alkyl, particularly lower alkyl such as Ci-C 6 alkyl or N-CH 2 OP(0)(ONa) 2 .
  • R 5 is an N-heterocyclyl, wherein a nitrogen atom in the N-heterocyclyl is optionally substituted by a substituent selected from alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -R 8 -OR 6 , -R 8 -C(0)R 6 ,
  • a carbon atom in the N-heterocyclyl is optionally substituted by a substituent selected from alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl,
  • cycloalkylalkynyl heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -R 8 -OR 6 , -R 8 -C(0)R 6 ,
  • Each R 6 and each R 7 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl,
  • heteroarylalkyl heteroarylalkenyl, or heteroarylalkynyl; or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an N-heteroaryl or an N-heterocyclyl.
  • Each R 8 is independently selected from a direct bond, a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain.
  • Each R 9 is independently selected from a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain.
  • R 10 is hydrogen or alkyl; m is 0, 1, 2, 3, 4 or 5; and n is 0, 1 or 2.
  • the presently disclosed compounds can exist as the parent compound, or a prodrug or pharmaceutically acceptable salt thereof, all of which can be in the form of hydrates, solvates, and N-oxides, as will be understood by a person or ordinary skill in the art.
  • One embodiment is a pharmaceutically acceptable salt form of a compound of formula I.
  • the pharmaceutically acceptable salts of the present disclosure can be formed by any acceptable method such as, by way of example: reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble or in a solvent such as water which is removed in vacuo; by freeze drying; or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.
  • the present disclosure includes within its scope solvates of the disclosed compounds and salts, such as hydrates of the compounds and their salts, for example, a hydrated formate salt or a hydrated xinafoate salt.
  • the JAK inhibitor is a 2,4-pyrimidinediamine having a formula
  • X and Y independently are heteroatoms or heteroatom- containing groups, particularly O, S, NH or N-alkyl, particularly lower alkyl, such as Ci-C 6 alkyl or N-CH 2 OP(0)(OH) 2 or a salt thereof, such as N-CH 2 OP(0)(ONa) 2 ;
  • ring A is aryl, such as phenyl, heteroaryl, such as pyridyl, or a fused ring system, such as, by way of example, an indazole ring system; each R 2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, or sulfon
  • ring A is phenyl. In certain embodiments, ring A is phenyl with at least one R 2 group para or meta to N2 of the
  • pyrimidinediamine, or ring A is phenyl and two R 2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered bicyclic ring system with ring A.
  • the JAK inhibitor according to formula II for use in combination with an immune enhancer is a compound listed in Table 1 or a pharmaceutically acceptable salt thereof.
  • the JAK inhibitor is a pyrimidin-2-amine having a general formula III
  • n 0, 1 or 2;
  • n 0, 1, 2, 3 or 4;
  • R 1 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, aryl, aralkyl, aralkenyl, aralkynyl, -R 8 -C(0)OR 6 , -R 9 -N(R 6 )R 7 or -R 9 -OR 6 ;
  • each R 2 when present, is independently selected from alkyl, halo, haloalkyl, cyano, nitro, -OR 6 , -N(R 6 ) 2 , -C(0)OR 6 or -C(0)N(R 6 ) 2 ;
  • each R 3 when present, is independently selected from alkyl, halo or haloalkyl;
  • R 4 is selected from aryl or heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substituents selected from oxo, alkyl, halo, haloalkyl, cyano, N-heterocyclyl, N-heteroaryl, aryl, -R 8 -OR 6a , -R 8 -S(0) r R 6a (where r is 0, 1 or 2), -R 8 -C(0)R 6a , -R 8 -C(0)OR 6a , -R 8 -C(0)N(R 6a )R 7a , -R 8 -N(R 6a )R 7a , -R 8 -N(R 6a )-R 9 -N(R 6a )R 7a , -R 8 -N(R 6a )-R 9 -OR 7a , -R 8 -N(R 6a )C(0)R 7a
  • R 5 is an N-heterocyclyl, wherein a nitrogen atom in the N-heterocyclyl is optionally substituted by a substituent selected from alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -R 8 -OR 6 , -R 8 -C(0)R 6 , -R 8 -C(0)OR 6 , -R 9 -N(R 6 )R 7
  • cycloalkylalkynyl heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -R 8 -OR 6 , -R 8 -C(0)R 6 ,
  • each R 6 and each R 7 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl,
  • each R 8 is independently selected from a direct bond, a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain;
  • each R 9 is independently selected from a straight or branched alkylene chain, a straight or branched alkenylene chain or a straight or branched alkynylene chain;
  • R 5 and a substituent on R 4 is a bridged N-heterocyclyl.
  • Ring A may be a phenyl or a pyridinyl ring.
  • the com ound has a formula Illa-IIIf
  • ring A is a phenyl or pyridinyl ring and R 5 is a bridged N-heterocyclyl.
  • R 5 is a bridged N-heterocyclyl.
  • each R 6 , R 7 , R 8 and R 9 is as previously defined for formula III; and where each R 20 is independently selected from hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, or two R 20 's, together with the common nitrogen to which they are both attached, form an N-heterocyclyl or an N-heteroaryl.
  • R 5 is a bridged N- heterocyclyl
  • an R 4 substituent is a bridged N-heterocyclyl
  • R 5 and an R 4 substituent are both bridged N-heterocyclyls.
  • R 5 is a bridged N-heterocyclyl.
  • R 5 is a bridged N-heterocyclyl or the R 4 substituent is an N- heterocyclyl
  • R 5 and the R 4 substituent need not be attached to ring A or R 4 , respectively, via a ring nitrogen of the bridged N-heterocyclyl, but rather can be attached via a ring carbon, for example.
  • a bridged N-heterocyclyl as R 5 or as an R 4 substituent is fused to another ring, part of a spiro ring system or both.
  • a bridged N-heterocyclyl as R 5 or as an R 4 substituent, alone or as part of a larger fused, spiro or combination ring system comprises a substructure geometry selected from [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], [3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2] or [2.2.1].
  • the bridged N-heterocyclyl as R 5 or as an R 4 substituent is the bridged N-heterocyclyl as R 5 or as an R 4 substituent
  • alkyl independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl,
  • cycloalkylalkynyl heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, -R 8 -OR 6 , -R 8 -C(0)R 6 ,
  • each R 6 , R 7 , R 8 and R 9 is as previously defined formula III; and where each R 20 is independently selected from hydrogen, alkyl, haloalkyl, cycloalkyl,
  • cycloalkylalkyl aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl, or two R 20 's, together with the common nitrogen to which they are both attached, form an N-heterocyclyl or an N-heteroaryl.
  • R 5 is a bridged N-heterocyclyl and R 4 is a heteroaryl with a bridged N-heterocyclyl.
  • R 5 is a bridged N-heterocyclyl containing an additional nitrogen
  • R 4 is a 5- or 6-membered heteroaryl and n is 0.
  • R 5 and the nitrogen bearing R 1 are in a para regiochemical relationship with each other and R 4 is selected from pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl triazolyl, tetrazinyl, tetrazolyl, pyrazolyl, pyrrolyl, imidazolyl or pyrazolyl.
  • R 4 is substituted with an amino-containing group, e.g.
  • R 6a , R 7a , R 8 and R 9 are as previously described with respect to formula III, or R 4 is substituted with a heterocyclyl, e.g. a piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl. In some examples, R 4 is substituted with a bridged N-heterocyclyl.
  • ring A and/or R 4 are substituted with up to three additional substituents selected from halo, alkyl, haloalkyl, cyano, nitro, hydroxy, -OR 25 , -N(R 25 )2, -C(0)OR 25 , -C(0)N(R 25 )2 or combinations thereof; where each R 25 is independently selected from hydrogen, alkyl, haloalkyl, cycloalkyl or cycloalkylalkyl.
  • Exemplary compounds according to formula III include the compounds listed below and pharmaceutically acceptable salts thereof:
  • the JAK inhibitors described herein can include functional groups that can be masked with progroups to create prodrugs. Such prodrugs are usually, but need not be, pharmacologically inactive until converted into their active drug form. Indeed, at least some of the compounds described herein include promoieties that are hydrolyzable or otherwise cleavable under conditions of use. For example, ester groups commonly undergo acid-catalyzed hydrolysis to yield the parent carboxylic acid when exposed to the acidic conditions of the stomach or base-catalyzed hydrolysis when exposed to the basic conditions of the intestine or blood. Thus, when administered to a subject orally, compounds that include ester moieties can be considered prodrugs of their corresponding carboxylic acid, regardless of whether the ester form is pharmacologically active.
  • the mechanism by which the progroups metabolize is not critical and can be caused, for example, by hydrolysis under the acidic conditions of the stomach, as described above, and/or by enzymes present in the digestive tract and/or tissues or organs of the body.
  • the progroup(s) can be selected to metabolize at a particular site within the body. For example, many esters are cleaved under the acidic conditions found in the stomach. Prodrugs designed to cleave chemically in the stomach to the active compounds can employ progroups including such esters. Alternatively, the progroups can be designed to metabolize in the presence of enzymes such as esterases, amidases, lipolases, and phosphatases, including ATPases and kinase, etc.
  • Progroups including linkages capable of metabolizing in vivo are well known and include, by way of example and not limitation, ethers, thioethers, silylethers, silylthioethers, esters, thioesters, carbonates,
  • a "precursor" group that is oxidized by oxidative enzymes such as, for example, cytochrome P450 of the liver, to a metabolizable group, can be selected.
  • any available functional moiety can be masked with a progroup to yield a prodrug.
  • Functional groups within the disclosed compounds that can be masked with progroups for inclusion in a promoiety include, but are not limited to, amines (primary and secondary), hydroxyls, sulfanyls (thiols), and carboxyls.
  • a wide variety of progroups, as well as the resultant promoieties, suitable for masking functional groups in active compounds to yield prodrugs are well-known in the art.
  • a hydroxyl functional group can be masked as a sulfonate, ester, or carbonate promoiety, which can be hydrolyzed in vivo to provide the hydroxyl group.
  • An amino functional group can be masked as an amide, carbamate, imine, urea, phosphenyl, phosphoryl, or sulfenyl promoiety, which can be hydrolyzed in vivo to provide the amino group.
  • a carboxyl group can be masked as an ester (including silyl esters and thioesters), amide, or hydrazide promoiety, which can be hydrolyzed in vivo to provide the carboxyl group.
  • the progroup is a phosphate-containing progroup of the formula -(CR d R d y-0-P(0)(OH)(OH), or a salt thereof, y is an integer ranging from 1 to 3, typically 1 or 2; and each R d is, independently of the others, selected from hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted methyl and substituted or unsubstituted benzyl. In a specific embodiment, each R d is, independently of the others, selected from hydrogen and unsubstituted lower alkyl.
  • Specific exemplary phosphate-containing progroups include -CH2-0-P(0)(OH)(OH) and -CH2CH2-0-P(0)(OH)(OH) and/or the corresponding salts.
  • Other specific examples of suitable progroups and their respective promoieties will be apparent to those of skill in the art. All of these progroups, alone or in combinations, can be included in the prodrugs.
  • the progroup(s) can be attached to any available primary or secondary amine, including, for example, the N2 nitrogen atom of the 2,4-pyrimidinediamine or the pyrimidin-2-amine, the N4 nitrogen atom of the 2,4-pyrimidinediamine, and/or a primary or secondary nitrogen atom included in a substituent on the 2,4-pyrimidinediamine or the pyrimidin-2-amine.
  • the identity of the progroup is not critical, provided that it can be metabolized under the desired conditions of use, for example, under the acidic conditions found in the stomach and/or by enzymes found in vivo, to yield a biologically active group, for example, the compounds as described herein.
  • the progroup can include virtually any known or later-discovered hydroxyl, amine or thiol protecting group.
  • Non- limiting examples of suitable protecting groups can be found, for example, in Protective Groups in Organic Synthesis, Greene & Wuts, 2 nd Ed., John Wiley & Sons, New York, 1991 (especially pages 10-142 (alcohols), 277-308 (thiols) and 309-405 (amines)), the disclosure of which is incorporated herein by reference.
  • compositions comprising a JAK inhibitor.
  • Pharmaceutical compositions described herein can be manufactured using conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilization processes.
  • the compositions can be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients, or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • One embodiment is a pharmaceutical formulation including at least one of the JAK inhibitors disclosed herein, or a prodrug thereof, and at least one pharmaceutically acceptable excipient, diluent, preservative, stabilizer, or mixture thereof.
  • the JAK inhibitors can be provided in a variety of formulations and dosages.
  • the compounds can be provided in a pharmaceutically acceptable form, including where the compound can be formulated in the pharmaceutical compositions per se, or in the form of a hydrate, solvate, N-oxide, or pharmaceutically acceptable salt, as described herein. Typically, such salts are more soluble in aqueous solutions than the corresponding free acids and bases, but salts having lower solubility than the corresponding free acids and bases can also be formed. It is to be understood that reference to the compound or "active" in discussions of formulations is also intended to include, where appropriate as known to those of skill in the art, formulation of the prodrugs of the disclosed compounds.
  • the compounds are provided as non-toxic, pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts are those salts that retain
  • Suitable pharmaceutically acceptable salts of the compounds described herein include acid addition salts such as those formed with hydrochloric acid, fumaric acid, p-toluenesulfonic acid, maleic acid, succinic acid, acetic acid, trifluoroacteic acid, citric acid, tartaric acid, carbonic acid, or phosphoric acid.
  • Salts of amine groups can also include quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl, or substituted alkyl moiety.
  • suitable pharmaceutically acceptable salts thereof can include metal salts such as alkali metal salts, for example, sodium or potassium salts; and alkaline earth metal salts, for example, calcium or magnesium salts.
  • compositions for the administration of the disclosed compounds can be conveniently presented in dosage unit form and can be prepared by any of the methods well known in the art of pharmacy.
  • the pharmaceutical compositions can be, for example, prepared by uniformly and intimately bringing an active compound or compounds into association with a liquid carrier, a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • the active object compound is included in an amount sufficient to produce the desired therapeutic effect.
  • the composition comprises from about 0.0001 to about 100 mg/kg/day, from about 0.001 to about 100 mg/kg/day; or from about 0.01 mg/kg/day to about 100 mg/kg/day of the compound.
  • the composition may also further comprise a pharmaceutically acceptable carrier, selected from lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol, starch, or combinations thereof.
  • the composition comprises about 1 to about 20 total weight percent of the compound and the one or more other therapeutic agents, and about 99 to about 80 weight percent of the pharmaceutically acceptable carrier.
  • the compound is provided as a dry powder, which may be encapsulated.
  • the compound has a particle size ranging from about 0.4 ⁇ to about 5
  • the compounds can be administered by oral, parenteral (for example, intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant), inhalation, spray, nasal, vaginal, rectal (for example, rectal suppository or enema), sublingual, urethral (for example, urethral suppository) or topical routes of administration (for example, gel, ointment, cream, aerosol, etc.) and can be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, excipients, and vehicles appropriate for each route of administration.
  • parenteral for example, intramuscular, intraperitoneal, intravenous, ICV, intracisternal injection or infusion, subcutaneous injection, or implant
  • inhalation spray
  • nasal vaginal
  • rectal for example, rectal suppository or enema
  • sublingual for example, urethral sup
  • administration can be, for example, orally, nasally, parenterally (e.g. , intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracisternally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.
  • Systemic formulations include those designed for administration by injection (for example, subcutaneous, intravenous, intramuscular, intrathecal, or intraperitoneal injection) as well as those designed for transdermal, transmucosal, oral, or pulmonary administration.
  • Useful injectable preparations include sterile suspensions, solutions, or emulsions of the active compound(s) in aqueous or oily vehicles.
  • the compositions can also contain formulating agents, such as suspending, stabilizing, and/or dispersing agents.
  • the formulations for injection can be presented in unit dosage form, for example, in ampules or in multidose containers, and can contain added preservatives.
  • the injectable formulation can be provided in powder form for reconstitution with a suitable vehicle, including but not limited to sterile pyrogen-free water, buffer, and dextrose solution, before use.
  • a suitable vehicle including but not limited to sterile pyrogen-free water, buffer, and dextrose solution, before use.
  • the active compound(s) can be dried by any art- known technique, such as lyophilization, and reconstituted prior to use.
  • the pharmaceutical compositions can take the form of, for example, lozenges, tablets, or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (for example, lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc, or silica);
  • pharmaceutically acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (for example, lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc, or silica);
  • disintegrants for example, potato starch or sodium starch glycolate
  • wetting agents for example, sodium lauryl sulfate
  • the tablets can be coated by methods well known in the art with, for example, sugars, films, or enteric coatings.
  • the pharmaceutical compositions containing at least one of the JAK inhibitors disclosed herein as active ingredient or prodrug thereof in a form suitable for oral use can also include, for example, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions can contain one or more agents including sweetening agents, flavoring agents, coloring agents, and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient (including drug and/or prodrug) in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients can be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents (for example, corn starch or alginic acid); binding agents (for example starch, gelatin, or acacia); and lubricating agents (for example, magnesium stearate, stearic acid, or talc).
  • the tablets can be left uncoated or they can be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • compositions described herein can also be in the form of oil-in- water emulsions.
  • Liquid preparations for oral administration can take the form of, for example, elixirs, solutions, syrups, or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by
  • compositions can take the form of tablets or lozenges formulated in the conventional manner.
  • the pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension.
  • This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a non- toxic parenterally-acceptable diluent or solvent.
  • acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • the active compound(s) can be formulated as solutions (for retention enemas), suppositories, or ointments containing conventional suppository bases such as cocoa butter or other glycerides.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are known in the art.
  • the disclosed compound(s) or prodrug(s) can be formulated as solutions, gels, ointments, creams, suspensions, etc., as are well-known in the art.
  • formulations can be included in a patch or other transdermal delivery system or formulation, for example, a formulation with ingredients specifically designed to aid transport of the compound through the skin and into the body tissues.
  • the active compound(s) or prodrug(s) can be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from pressurized packs or a nebulizer with the use of a suitable propellant (for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane,
  • a suitable propellant for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane,
  • the dosage unit can be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • a suitable powder base such as lactose or starch.
  • the drug product Prior to use in a dry powder or suspension formulation, the drug product typically is micronized to a size suitable for delivery by inhalation (typically less than about 5 microns). This may be achieved as is known to those of skill in the art by an appropriate method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing, spray drying and the like.
  • the compound(s) or prodrug(s) can be formulated as a depot preparation for administration by implantation or intramuscular injection.
  • the active ingredient can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (for example, as a sparingly soluble salt).
  • transdermal delivery systems manufactured as an adhesive disc or patch which slowly releases the active compound(s) for percutaneous absorption can be used.
  • permeation enhancers can be used to facilitate transdermal penetration of the active compound(s). Suitable transdermal patches are described in, for example, U.S. Patent No. 5,407,713.; U.S. Patent No.
  • Liposomes and emulsions are well-known examples of delivery vehicles that can be used to deliver active compound(s) or prodrug(s).
  • Certain organic solvents such as dimethylsulfoxide (DMSO) can also be employed, although usually at the cost of greater toxicity.
  • DMSO dimethylsulfoxide
  • Immunooncology focuses on therapies that aid a body's immune system to generate an effective immune response against cancer.
  • An immunooncology agent is a therapeutic agent that can enhance or improve a body's innate potential for generating such an effective immune response.
  • immunooncology agents include, but are not limited to, antibodies, kinase inhibitors and dioxygenase inhibitors.
  • Antibodies such as anti-PD-1 and/or anti-PD-Ll antibodies, act to potentiate the anticancer response of the immune system.
  • immunooncology agents potentiate an antitumor T cell response by inhibiting the interaction of an inhibitory receptor on the T cells, such as PD-1, with a ligand on the tumor cell, such as PD-L1.
  • Dioxygenase inhibitors such as indole dioxygenase inhibitors, inhibit immunosuppressive enzymes, such as indoleamine-2,3-dioxygenase. These enzymes can inhibit a destructive T cell response against a cancer cell, thereby allowing the cancer cell to escape from an immunologically mediated rejection.
  • the PI3K signaling pathway can help certain cancers escape rejection by the immune system.
  • Certain kinase inhibitors, such as PI3K inhibitors can disrupt this signaling pathway, thereby aiding detection of the cancer cells by the immune system.
  • the immunooncology agent is an anti-PD-1 and/or anti-PD-Ll antibody, such as nivolumab, pembrolizumab, lambrolizumab, pidilizumab, BMS-936559, MPDL3280A, AMP-224 or MEDI4736; anti-CTLA-4 antibody, such as ipilimumab or tremelimumab; anti-KIR antibody, such as lirilumab; anti-LAG3 antibody, such as BMS-986016; anti-CD137 antibody, such as urelumab; anti-SLAM antibody, such as anti-SLAMF7 for example elotuzumab; PI3K inhibitors, such as idelalisib, AZD8186, INCB40093 and INCB50465; and indole dioxygenase (IDO) and/or tryptophan dioxygenase inhibitors (TDO), such as 1- methyltryp
  • IDO
  • two or more immunooncology agents are combined with a JAK inhibitor.
  • the immunooncology agents in such combinations act on different targets.
  • an anti-PD-1 agent such as nivolumab
  • an anti-CTLA-4 agent such as ipilimumab is particularly useful in combination with a JAK inhibitor.
  • Disclosed embodiments of the present application particularly concern combination therapy concerning administering one or more disclosed JAK inhibitors in combination with one or more immunooncology agents, such as an anti-PD-1, anti-PD-Ll, PI3K inhibitor, indole dioxygenase (IDO) inhibitor.
  • immunooncology agents such as an anti-PD-1, anti-PD-Ll, PI3K inhibitor, indole dioxygenase (IDO) inhibitor.
  • the embodiments of disclosed combination may be used alone, in combination with one or more additional JAK inhibitors and/or immunooncology agents, or as an adjunct to, or in combination with, other established therapies.
  • embodiments of the disclosed combination may be used in combination with at least one other, or plural other, therapeutic agents useful for the disorder or condition being treated. These compounds may be administered simultaneously, sequentially in any order, by the same route of administration, or by a different route.
  • a second therapeutic agent used in combination with the JAK inhibitor, the immunooncology agent, or both is an analgesic, an antibiotic, an anticoagulant, an antibody, an anti-inflammatory agent, an immunosuppressant, a guanylate cyclase-C agonist, an intestinal secretagogue, an antiviral, anticancer, antifungal, or a combination thereof.
  • the antiinflammatory agent may be a steroid or a nonsteroidal anti-inflammatory agent.
  • the nonsteroidal anti-inflammatory agent is selected from aminosalicylates, cyclooxygenase inhibitors, diclofenac, etodolac, famotidine, fenoprofen, flurbiprofen, ketoprofen, ketorolac, ibuprofen, indomethacin, meclofenamate, mefenamic acid, meloxicam, nambumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin, or a combination thereof.
  • the immunosuppressant is mercaptopurine, a corticosteroid, an alkylating agent, a calcineurin inhibitor, an inosine monophosphate dehydrogenase inhibitor, antilymphocyte globulin, antithymocyte globulin, an anti-T-cell antibody, or a combination thereof.
  • the antibody is infliximab.
  • the JAK inhibitor, the immunooncology agent, or both may be used in combination with other anti-cancer or cytotoxic agents.
  • the present combinations are further combined with one or more agents from the current standard of care for a given malignancy.
  • the following table displays exemplary cancers treatable in the combination therapies of the invention and lists additional treatments for use in combination with the JAK inhibitor and immunooncology agent combinations disclosed herein:
  • anti-cancer and anti-neoplastic compounds for use with the presently disclosed inhbitors include, but are not limited to, alkylating agents, antimetabolites, vinca alkyloids, taxanes, antibiotics, enzymes, cytokines, platinum coordination complexes, substituted ureas, kinase inhibitors, hormones and hormone antagonists.
  • alkylating agents include, without limitation, mechlorothamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, ethyleneimines, methylmelamines, alkyl sulfonates (e.g., busulfan), and carmustine.
  • Exemplary antimetabolites include, by way of example and not limitation, folic acid analog methotrexate; pyrmidine analog fluorouracil, cytosine arbinoside; purine analogs mercaptopurine, thioguanine, and azathioprine.
  • Exemplary vinca alkyloids include, by way of example and not limitation, vinblastine, vincristine, paclitaxel, and colchicine.
  • Exemplary antibiotics include, by way of example and not limitation, actinomycin D, daunorubicin, and bleomycin.
  • An exemplary enzyme effective as an anti-neoplastic agent includes L-asparaginase.
  • Exemplary coordination compounds include, by way of example and not limitation, cisplatin and carboplatin.
  • hormones and hormone related compounds include, by way of example and not limitation, adrenocorticosteroids prednisone and dexamethasone; aromatase inhibitors amino glutethimide, formestane, and anastrozole; progestin compounds hydroxyprogesteron caproate, medroxyprogesterone; and anti- estrogen compound tamoxifen.
  • CTLA 4 antibodies that can be used in combination with the JAK inhibitor, the immunooncology agent, or both, is ipilimumab, marketed as YERVOY® by Bristol-Myers Squibb.
  • Additional anti-proliferative compounds useful in combination with the JAK inhibitor, the immunooncology agent, or both include, by way of example and not limitation, antibodies directed against growth factor receptors (e.g., anti-Her2); and cytokines such as interferon-a and interferon- ⁇ , interleukin-2, and GM-CSF.
  • growth factor receptors e.g., anti-Her2
  • cytokines such as interferon-a and interferon- ⁇ , interleukin-2, and GM-CSF.
  • BCL2 B-cell lymphoma 2
  • analgesics - morphine, fentanyl, hydromorphone, oxycodone, codeine, acetaminophen, hydrocodone, buprenorphine, tramadol, venlafaxine, flupirtine, meperidine, pentazocine, dextromoramide, dipipanone;
  • antibiotics - aminoglycosides e.g., amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, and paromycin
  • carbapenems e.g., ertapenem, doripenem, imipenem, cilastatin, and meropenem
  • cephalosporins e.g., cefadroxil, cefazolin, cefalotin, cephalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, and cefobiprole), glycopeptides (e.g., teicoplanin, vancomycin
  • ampicillin/sulbactam, piperacillin/tazobactam, and ticarcillin/clavulanate polypeptides (e.g., bacitracin, colistin, and polymyxin B), quinolones (e.g., ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, and temafloxacin), sulfonamides (e.g., mafenide,
  • sulfonamidochrysoidine sulfacetamide, sulfadiazine, silver sulfadiazine, sulfamethizole, sulfamethoxazole, sulfanamide, sulfasalazine, sulfisoxazole, trimethoprim, and trimethoprim- sulfamethoxaxzole), tetracyclines (e.g., demeclocycline, doxycycline, minocycline, oxytetracycline, and tetracycline), antimycobacterial compounds (e.g., clofazimine, dapsone, capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifampicin (rifampin), rifabutin, rifapentine, and streptomycin), and others, such as ar
  • antibodies - anti-TNF-a antibodies e.g., infliximab (RemicadeTM), adalimumab, golimumab, certolizumab; anti-B cell antibodies, e.g., rituximab; anti-IL-6 antibodies, e.g., tocilizumab; anti-IL-1 antibodies, e.g., anakinra; anti PD-1 and/or anti-PD-Ll antibodies, e.g.
  • infliximab ResmicadeTM
  • adalimumab golimumab
  • certolizumab certolizumab
  • anti-B cell antibodies e.g., rituximab
  • anti-IL-6 antibodies e.g., tocilizumab
  • anti-IL-1 antibodies e.g., anakinra
  • anti PD-1 and/or anti-PD-Ll antibodies e.g.
  • nivolumab pembrolizumab, pidilizumab, BMS-936559, MPDL3280A, AMP-224, MEDI4736; ixekizumab, brodalumab, ofatumumab, sirukumab, clenoliximab, clazakiumab, fezakinumab, fletikumab, mdressimumab, ocrelizumab, sarilumab, secukinumab, toralizumab, zanolimumab; anticoagulants - warfarin (CoumadinTM), acenocoumarol, phenprocoumon, atromentin, phenindione, heparin, fondaparinux, idraparinux, rivaroxaban, apixaban, hirudin, lepirudin, bivalirudin, argatrobam, dabigatran, ximelagatran, bat
  • anti-inflammatory agents - steroids e.g., budesonide
  • nonsteroidal anti-inflammatory agents e.g., aminosalicylates (e.g., sulfasalazine, mesalamine, olsalazine, and balsalazide), cyclooxygenase inhibitors (COX-2 inhibitors, such as rofecoxib, celecoxib), diclofenac, etodolac, famotidine, fenoprofen, flurbiprofen, ketoprofen, ketorolac, ibuprofen, indomethacin,
  • COX-2 inhibitors such as rofecoxib, celecoxib
  • diclofenac etodolac
  • famotidine fenoprofen
  • flurbiprofen ketoprofen
  • ketorolac ketorolac
  • ibuprofen indomethacin
  • meclofenamate mefenamic acid, meloxicam, nambumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin;
  • immunosuppressants - mercaptopurine corticosteroids such as dexamethasone, hydrocortisone, prednisone, methylprednisolone and prednisolone, alkylating agents such as cyclophosphamide, calcineurin inhibitors such as cyclosporine, sirolimus and tacrolimus, inhibitors of inosine monophosphate dehydrogenase (IMPDH) such as mycophenolate, mycophenolate mofetil and azathioprine, and agents designed to suppress cellular immunity while leaving the recipient's humoral immunologic response intact, including various antibodies (for example, antilymphocyte globulin (ALG), anti thymocyte globulin (ATG), monoclonal anti-T-cell antibodies (OKT3)) and irradiation.
  • corticosteroids such as dexamethasone, hydrocortisone, prednisone, methylprednisolone and predn
  • Azathioprine is currently available from Salix Pharmaceuticals, Inc. under the brand name Azasan; mercaptopurine is currently available from Gate Pharmaceuticals, Inc. under the brand name Purinethol; prednisone and prednisolone are currently available from Roxane Laboratories, Inc.; Methyl prednisolone is currently available from Pfizer; sirolimus (rapamycin) is currently available from Wyeth-Ayerst under the brand name Rapamune; tacrolimus is currently available from Fujisawa under the brand name Prograf; cyclosporine is current available from Novartis under the brand name Sandimmune and Abbott under the brand name Gengraf; IMPDH inhibitors such as mycophenolate mofetil and mycophenolic acid are currently available from Roche under the brand name Cellcept and Novartis under the brand name Myfortic; azathioprine is currently available from Glaxo Smith Kline under the brand name Imuran; and antibodies are currently available from Ortho Biotech under the brand name Orthoclon
  • Guanylate cyclase - C receptor agonists or intestinal secretagogues-for example linaclotide sold under the name Linzess.
  • These various agents can be used in accordance with their standard or common dosages, as specified in the prescribing information accompanying commercially available forms of the drugs (see also, the prescribing information in the 2006 Edition of The Physician's Desk Reference), the disclosures of which are incorporated herein by reference.
  • Embodiments of the disclosed combination can be used to treat and/or prevent certain diseases and/or disorders such as cell proliferative disorders including cancer.
  • Compounds of formula I, salts, solvates, prodrug(s) thereof, or compositions thereof will generally be used in combination with at least one immunooncology agent.
  • the activity of a specified compound as an inhibitor of a JAK kinase can be assessed in vitro or in vivo.
  • the activity of a specified compound can be tested in a cellular assay.
  • Suitable assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of a JAK kinase.
  • a compound is said to inhibit an activity of a JAK kinase if it inhibits the phosphorylation or ATPase activity of a JAK kinase with an IC50 of about 20 ⁇ or less.
  • the biological activity of the disclosed compounds may further be characterized by assaying the effect of the compounds on the proliferative response of primary human T-cells.
  • primary human T-cells derived from peripheral blood and pre-activated through stimulation of the T-cell receptor and CD28, proliferate in culture in response to the cytokine Interleukin-2 (IL-2).
  • IL-2 cytokine Interleukin-2
  • This proliferative response is dependent on the activation of JAKl and JAK3 tyrosine kinases, which phosphorylate and activate the transcription factor Stat-5.
  • the primary human T-cells are incubated with the compounds in the presence of IL-2 for 72 hours and at the assay endpoint intracellular ATP concentrations are measured to assess cell viability. A reduction in cell proliferation compared to control conditions is indicative of inhibition of the JAK kinase pathway.
  • Activity of exemplary compounds in this primary T-cell assay are provided in Table 2.
  • the biological activity of the compounds according to formula I may additionally be characterized by assaying the effect of the compounds described herein on A549 lung epithelial cells and U937 cells.
  • A549 lung epithelial cells and U937 cells up-regulate ICAM-1 (CD54) surface expression in response to a variety of different stimuli. Therefore, using ICAM-1 expression as readout, test compound effects on different signaling pathways can be assessed in the same cell type.
  • Stimulation with IL- ⁇ through the IL- ⁇ receptor activates the TRAF6 / NFKB pathway resulting in up-regulation of ICAM-1.
  • IFNy induces ICAM-1 up-regulation through activation of the JAK1/JAK2 pathway.
  • the up-regulation of ICAM-1 can be quantified by flow cytometry across a compound dose curve and EC50 values are calculated.
  • Compounds according to formula I, thereof, generally inhibit the JAK kinase pathway with an IC50 in the range of about 1 mM or less, as measured in the assays described herein.
  • IC50 in the range of about 1 mM or less
  • compounds which exhibit lower IC50S for example on the order of 100 ⁇ , 75 ⁇ , 50 ⁇ , 40 ⁇ , 30 ⁇ , 20 ⁇ , 15 ⁇ , 10 ⁇ , 5 ⁇ , 1 ⁇ , 500 ⁇ , 100 ⁇ , 10 ⁇ , 1 ⁇ , or even lower, can be particularly useful in therapeutic applications.
  • the compound can be assayed for activity with the desired cell type and counter-screened for a lack of activity against other cell types.
  • the desired degree of "inactivity" in such counter screens, or the desired ratio of activity vs. inactivity may vary for different situations, and can be selected by the user.
  • the disclosed JAK inhibitors also typically inhibit IL-4 stimulated expression of CD23 in B -cells with an IC50 in the range of about 20 ⁇ or less, typically in the range of about 10 ⁇ , 1 ⁇ , 500 nM, 100 nM, 10 nM, 1 nM, or even lower.
  • Certain disclosed compounds may have an IC50 of less than or equal to 5 ⁇ , greater than 5 ⁇ but less than 20 ⁇ , greater than 20 ⁇ , or greater than 20 ⁇ but less than 50 ⁇ .
  • the disclosed JAK inhibitors, or pharmaceutically acceptable salts, hydrates, solvates, N-oxides and/or prodrugs thereof also typically inhibit an activity of an human primary T-cells with an IC50 in the range of about 20 ⁇ or less, typically in the range of about 10 ⁇ , 1 ⁇ , 500 nM, 100 nM, 10 nM, 1 nM, or even lower.
  • the IC50 against human primary T-cells can be determined in a standard in vitro assay with isolated human primary T-cells.
  • a compound according to formula I has an IC50 of less than or equal to 5 ⁇ , greater than 5 ⁇ but less than 20 ⁇ , greater than 20 ⁇ , or greater than 20 ⁇ but less than 50 ⁇ .
  • the compounds according to formula I, or pharmaceutically acceptable salts, hydrates, solvates, N-oxides and/or prodrugs thereof also typically inhibit expression of ICAM1 (CD54) induced by IFNy exposure in U937 or A549 cells with an IC50 in the range of about 20 ⁇ or less, typically in the range of about 10 ⁇ , 1 ⁇ , 500 nM, 100 nM, 10 nM, 1 nM, or even lower.
  • the IC50 against expression of ICAM (CD54) in IFNy stimulated cells can be determined in a functional cellular assay with an isolated A549 or U937 cell line.
  • the compounds have an IC50 of less than or equal to 20 ⁇ , greater than 20 ⁇ , or greater than 20 ⁇ but less than 50 ⁇ .
  • cell proliferative disorder refers to a disorder characterized by abnormal proliferation of cells.
  • a cell proliferative disorder does not imply any limitation with respect to the rate of cell growth, but merely indicates loss of normal controls that affect growth and cell division.
  • cells of a cell proliferative disorder can have the same cell division rates as normal cells but do not respond to signals that limit such growth.
  • neoplasm or tumor which is an abnormal growth of tissue.
  • Cancer refers to any of various malignant neoplasms characterized by the proliferation of cells that have the capability to invade surrounding tissue and/or metastasize to new colonization sites.
  • the antiproliferative effect of a combination therapy as disclosed herein may be assessed by administering embodiments of the combination to a cultured tumor cell line.
  • administration of a combination comprising a JAK inhibitor according to formula I and an immunooncology agent, may be simply achieved by contacting the cells in culture with the individual components of the combination in respective amounts effective to inhibit cell proliferation.
  • the antiproliferative effect of an embodiment of the disclosed combination may be assessed by administering the combination to an animal in an approved in vivo model for cell proliferation.
  • In vitro or in vivo administration of a disclosed combination may comprise administering the JAK inhibitor and imunooncology agent substantially simultaneously.
  • administration may comprise administering the components of the combination, i.e. the JAK inhibitor and the immunooncology agent, sequentially, in any order. With respect to a sequential administration, the second component, and any subsequent components, are
  • a subject may experience a synergistic therapeutic effect upon administration of the combination, i.e. a therapeutic effect that is greater than the sum of the individual therapeutic effects of each component.
  • cell proliferative disorders treatable with a combination comprising a compound according to formula I, or pharmaceutically acceptable salts, hydrates, solvates, N- oxides and/or prodrugs thereof, and an immunooncology agent, relate to any disorder characterized by aberrant cell proliferation.
  • these include various tumors and cancers, benign or malignant, metastatic or non-metastatic.
  • Cell proliferative disorders include a variety of cancers, including, among others, cancer of the tongue, mouth, pharynx, esophagus, stomach, small intestine, colon, rectum, anus, liver, gallbladder, pancreas, larynx, lung and bronchus, bones and joints including synovial sarcoma and osteosarcoma, melanomas including basal cell carcinoma, squamous carcinoma, breast, cervix, endometrium, ovary, vulva, vagina, prostate, testis, penis, urinary bladder, kidney and renal pelvis, ureter, eye, brain including glioma, glioblastoma, astrocytoma, neuroblastoma, medulloblastoma, and thyroid.
  • cancers including, among others, cancer of the tongue, mouth, pharynx, esophagus, stomach, small intestine, colon, rectum, anus, liver, gallbladder
  • cell proliferative disorders treatable with embodiments of the disclosed combination include, but are not limited to, the following: a) proliferative disorders of the breast, which include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma, lobular carcinoma in situ and metastatic breast cancer;
  • proliferative disorders of the skin which include, but are not limited to, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma;
  • proliferative disorders of the respiratory tract include, but are not limited to, small cell and non-small cell lung carcinoma, bronchial adema, pleuropulmonary blastoma and malignant mesothelioma;
  • proliferative disorders of the brain include, but are not limited to, brain stem and hyptothalamic glioma, cerebellar and cerebral astrocytoma, medullablastoma, ependymal tumors, oligodendroglial, meningiomas and neuroectodermal and pineal tumors;
  • proliferative disorders of the male reproductive organs which include, but are not limited to, prostate cancer, testicular cancer and penile cancer
  • proliferative disorders of the female reproductive organs which include, but are not limited to, uterine cancer (endometrial), cervical, ovarian, vaginal, vulval cancers, uterine sarcoma and ovarian germ cell tumor;
  • proliferative disorders of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, stomach (gastric), pancreatic cancer, pancreatic cancer- Islet cell, rectal, small-intestine and salivary gland cancers;
  • liver proliferative disorders of the liver, which include, but are not limited to,
  • hepatocellular carcinoma cholangiocarcinoma, mixed hepatocellular cholangiocarcinoma, primary liver cancer and metastatic liver cancer;
  • proliferative disorders of the eye which include, but are not limited to, intraocular melanoma, retinoblastoma, and rhabdomyosarcoma;
  • proliferative disorders of the head and neck which include, but are not limited to, laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancers, and lip and oral cancer, squamous neck cancer, metastatic paranasal sinus cancer;
  • lymphocytic cells which include, but are not limited to, various T cell and B cell lymphomas, non-Hodgkins lymphoma, cutaneous T cell lymphoma,
  • leukemias which include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia,
  • m) proliferative disorders of the thyroid which include, but are not limited to, thyroid cancer, thymoma, malignant thymoma, medullary thyroid carcinomas, papillary thyroid
  • MEN2A multiple endocrine neoplasia type 2A
  • MEN2B multiple endocrine neoplasia type 2B
  • FMTC familial medullary thyroid carcinoma
  • carcinoids carcinoids
  • n) proliferative disorders of the urinary tract which include, but are not limited to, bladder cancer;
  • sarcomas which include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma;
  • kidneys proliferative disorders of the kidneys, which include, but are not limited to, renal cell carcinoma, clear cell carcinoma of the kidney; and renal cell adenocarcinoma;
  • lymphoblastic leukemia B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
  • B- cell prolymphocytic leukemia lymphoplasmacytic lymphoma
  • splenic marginal zone B-cell lymphoma hairy cell leukemia
  • plasma cell myeloma/plasmacytoma extranodal marginal zone B- cell lymphoma of MALT type
  • nodal marginal zone B-cell lymphoma follicular lymphoma
  • mantle-cell lymphoma diffuse large B-cell lymphoma
  • mediastinal large B-cell lymphoma primary effusion lymphoma and Burkitt's lymphoma/Burkitt cell leukemia
  • T-cell prolymphocytic leukemia T-cell prolymphocytic leukemia
  • T-cell granular lymphocytic leukemia aggressive NK-cell leukemia
  • adult T-cell lymphoma/leukemia HTLV-1
  • extranodal NK T-cell lymphoma nasal type, enteropathy-type T-cell lymphoma, hepatosplenic gamma-delta T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, mycosis fungoides/Sezary syndrome, anaplastic large-cell lymphoma, T/null cell, primary cutaneous type, peripheral T-cell lymphoma, not otherwise characterized, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma, T/null cell, and primary systemic type;
  • Hodgkin's lymphoma grades 1 and 2
  • lymphocyte-rich classical Hodgkin' s lymphoma mixed cellularity Hodgkin's lymphoma, and lymphocyte depletion Hodgkin's lymphoma
  • myelogenous leukemia e.g. , Philadelphia chromosome positive (t(9;22)(qq34;ql 1)
  • multiple myeloma chronic neutrophilic leukemia, chronic eosinophilic leukemia/hypereosinophilic syndrome, chronic idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myelomonocytic leukemia, atypical chronic myelogenous leukemia, juvenile
  • myelomonocytic leukemia myelomonocytic leukemia, refractory anemia with ringed sideroblasts and without ringed sideroblasts, refractory cytopenia (myelodysplastic syndrome) with multilineage dysplasia, refractory anemia (myelodysplastic syndrome) with excess blasts, 5q-syndrome, and
  • tumor cell lines derived from human tumors and available for use in the in vivo studies include, but are not limited to, leukemia cell lines (e.g. , CCRF-CEM, HL-60(TB), K-562, MOLT-4, RPM1-8226, SR, P388 and P388/ADR); non-small cell lung cancer cell lines (e.g., A549/ATCC, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, NCI-H322M, NCI-H460, NCI- H522 and LXFL 529); small cell lung cancer cell lines ( ⁇ ?.g.,DMS 114 and SHP-77); colon cancer cell lines (e.g., COLO 205, HCC-2998, HCT-116, HCT-15, HT29, KM12, SW-620, DLD-1 and KM20L2); central nervous system (CNS) cancer cell lines (e.g., SF-268,
  • ovarian cancer cell lines e.g., IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8 and SK- OV-3
  • renal cancer cell lines e.g., 786-0, A498, ACHN, CAKI-1, RXF 393, SN12C, TK-10, UO- 31, RXF-631 and SN12K1
  • prostate cancer cell lines e.g., PC-3 and DU-145
  • breast cancer cell lines e.g., MCF7, NCI/ ADR- RES, MDA-MB-231/ATCC, HS 578T, MDA-MB-435, BT-549, T- 47D and MDA-MB-468
  • thyroid cancer cell lines e.g., SK-N-SH.
  • the cell proliferative disorder treated by the disclosed combination is a hematopoietic neoplasm, which is aberrant growth of cells of the hematopoietic system.
  • Hematopoietic malignancies can have its origins in pluripotent stem cells, multipotent progenitor cells, oligopotent committed progenitor cells, precursor cells, and terminally differentiated cells involved in hematopoiesis. Some hematological malignancies are believed to arise from hematopoietic stem cells, which have the ability for self renewal. For instance, cells capable of developing specific subtypes of acute myeloid leukemia (AML) upon transplantation display the cell surface markers of hematopoietic stem cells, implicating hematopoietic stem cells as the source of leukemic cells.
  • AML acute myeloid leukemia
  • Blast cells that do not have a cell marker characteristic of hematopoietic stem cells appear to be incapable of establishing tumors upon transplantation (Blaire et al., 1997, Blood 89:3104-3112).
  • the stem cell origin of certain hematological malignancies also finds support in the observation that specific chromosomal abnormalities associated with particular types of leukemia can be found in normal cells of hematopoietic lineage as well as leukemic blast cells.
  • the reciprocal translocation t(9q34;22ql l) associated with approximately 95% of chronic myelogenous leukemia appears to be present in cells of the myeloid, erythroid, and lymphoid lineage, suggesting that the chromosomal aberration originates in hematopoietic stem cells.
  • a subgroup of cells in certain types of CML displays the cell marker phenotype of hematopoietic stem cells.
  • hematopoietic neoplasms often originate from stem cells, committed progenitor cells or more terminally differentiated cells of a developmental lineage can also be the source of some leukemias.
  • forced expression of the fusion protein Bcr/Abl associated with chronic myelogenous leukemia
  • common myeloid progenitor or granulocyte/macrophage progenitor cells produces a leukemic-like condition.
  • chromosomal aberrations associated with subtypes of leukemia are not found in the cell population with a marker phenotype of hematopoietic stem cells, but are found in a cell population displaying markers of a more differentiated state of the hematopoietic pathway (Turhan et al., 1995, Blood 85:2154-2161).
  • committed progenitor cells and other differentiated cells may have only a limited potential for cell division
  • leukemic cells may have acquired the ability to grow unregulated, in some instances mimicking the self -renewal characteristics of hematopoietic stem cells (Passegue et al., Proc. Natl. Acad. Set USA, 2003, 100:11842-9).
  • the hematopoietic neoplasm is a lymphoid neoplasm, where the abnormal cells are derived from and/or display the characteristic phenotype of cells of the lymphoid lineage.
  • Lymphoid neoplasms can be subdivided into B-cell neoplasms, T and NK -cell neoplasms, and Hodgkin's lymphoma.
  • B-cell neoplasms can be further subdivided into precursor B-cell neoplasm and mature/peripheral B-cell neoplasm.
  • Exemplary B-cell neoplasms are precursor B- lymphoblastic leukemia/lymphoma (precursor B-cell acute lymphoblastic leukemia) while exemplary mature/peripheral B-cell neoplasms are B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone B-cell lymphoma, hairy cell leukemia, plasma cell myeloma/plasmacytoma, extranodal marginal zone B-cell lymphoma of MALT type, nodal marginal zone B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, diffuse large B-cell lymphoma, mediastinal large B- cell lymphoma, primary effusion lymphoma, and Burkitt' s lymphoma/Burkitt cell leukemia.
  • T-cell neoplasms are precursor T- lymphoblastic lymphoma/leukemia (precursor T-cell acute lymphoblastic leukemia) while exemplary mature (peripheral) T-cell neoplasms are T-cell prolymphocytic leukemia T-cell granular lymphocytic leukemia, aggressive NK-cell leukemia, adult T-cell lymphoma/leukemia (HTLV-1), extranodal NK T-cell lymphoma, nasal type, enteropathy-type T-cell lymphoma, hepatosplenic gamma-delta T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, Mycosis fungoides/Sezary syndrome, Anaplastic large-cell lymphoma, T/null cell, primary cutaneous type, Peripheral T-cell lymphoma, not otherwise characterized, Angioi
  • the third member of lymphoid neoplasms is Hodgkin's lymphoma, also referred to as Hodgkin's disease.
  • Exemplary diagnosis of this class that can be treated with the compounds of the disclosure, include, among others, nodular lymphocyte- predominant Hodgkin's lymphoma, and various classical forms of Hodgkin's disease, exemplary members of which are Nodular sclerosis Hodgkin's lymphoma (grades 1 and 2), Lymphocyte-rich classical Hodgkin's lymphoma, Mixed cellularity Hodgkin's lymphoma, and Lymphocyte depletion Hodgkin's lymphoma.
  • any of the lymphoid neoplasms that are associated with aberrant JAK activity can be treated with embodiments of the disclosed combination comprising a JAK inhibitory compound.
  • the hematopoietic neoplasm is a myeloid neoplasm.
  • This group comprises a large class of cell proliferative disorders involving or displaying the characteristic phenotype of the cells of the myeloid lineage.
  • Myeloid neoplasms can be subdivided into myeloproliferative diseases, myelodysplastic/myeloproliferative diseases, myelodysplastic syndromes, and acute myeloid leukemias.
  • Exemplary myeloproliferative diseases are chronic myelogenous leukemia (e.g.
  • myelodysplastic/myeloproliferative diseases are chronic myelomonocytic leukemia, atypical chronic myelogenous leukemia, and juvenile myelomonocytic leukemia.
  • myelodysplastic syndromes are refractory anemia, with ringed sideroblasts and without ringed sideroblasts, refractory cytopenia (myelodysplastic syndrome) with multilineage dysplasia, refractory anemia (myelodysplastic syndrome) with excess blasts, 5q- syndrome, and
  • any of the myeloid neoplasms that are associated with aberrant JAK activity can be treated with a disclosed combination comprising a JAK inhibitory compound.
  • embodiments of the disclosed combination can be used to treat acute myeloid leukemias (AML), which represent a large class of myeloid neoplasms having its own subdivision of disorders. These subdivisions include, among others, AMLs with recurrent cytogenetic translocations, AML with multilineage dysplasia, and other AML not otherwise categorized.
  • AML acute myeloid leukemias
  • Exemplary AMLs with recurrent cytogenetic translocations include, among others, AML with t(8;21)(q22;q22), AML 1 (CBF-alpha)/ETO, Acute promyelocytic leukemia (AML with t(15; 17)(q22;ql 1-12) and variants, PML/RAR-alpha), AML with abnormal bone marrow eosinophils (inv(16)(pl3q22) or t(16; 16)(pl3 ;ql l), CBFb/MYHl lX), and AML with l lq23 (MLL) abnormalities.
  • AML with t(8;21)(q22;q22) AML 1 (CBF-alpha)/ETO
  • Acute promyelocytic leukemia AML with t(15; 17)(q22;ql 1-12
  • PML/RAR-alpha Acute promyelocytic le
  • Exemplary AML with multilineage dysplasia are those that are associated with or without prior myelodysplastic syndrome.
  • Other acute myeloid leukemias not classified within any definable group include, AML minimally differentiated, AML without maturation, AML with maturation, Acute myelomonocytic leukemia, Acute monocytic leukemia, Acute erythroid leukemia, Acute megakaryocytic leukemia, Acute basophilic leukemia, and Acute panmyelosis with myelofibrosis.
  • nivolumab sodium (5-((2-((4-fluoro-3-methoxy-5- methylphenyl)amino)-5-methylpyrimidin- 4-yl) amino)-2-oxobenzo [d] oxazol- 3 (2H) - yl)methyl phosphate
  • pembrolizumab 5-((2-((4-fluoro-3-methoxy-5- methylphenyl)amino)-5-methylpyrimidin-
  • ipilimumab, nivolumab 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(3- methyl-4-((lS,4S)-5-methyl-2,5- diazabicyclo [2.2.1 ]heptan-2- yl)phenyl)pyrimidin-2-amine
  • ipilimumab sodium (5-((2-((4-fluoro-3,5- dimethy lpheny 1) amino) - 5 - methylpyrimidin-4-yl)amino)-2- oxobenzo [d]oxazol-3 (2H)-yl)methyl
  • Animal models useful for testing the efficacy of combinations comprising a JAK inhibitor and an immunooncology agent, or the efficacy of the individual components of the combination, to treat or prevent the various diseases or conditions described above are well-known in the art.
  • suitable animal models of systemic mastocytosis are described in O' Keefe et al , (1987), /. Vet. Intern. Med. l(2):75-80 and Bean-Knudsen et al. , (1989), Vet. Pathol. 26(l):90-92.
  • Suitable animal models of B-cell lymphoma are described in Hough et al, (1998), Proc. Natl. Acad.
  • the embodiments of the disclosed combination can be administered therapeutically to achieve therapeutic benefit or prophylactically to achieve prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated and/or eradication or amelioration of one or more of the symptoms associated with the underlying disorder such that the subject reports an improvement in feeling or condition, notwithstanding that the subject may still be afflicted with the underlying disorder.
  • prophylactic benefit is meant prevention or delayed onset of a disorder.
  • the combination can be administered to a subject at risk of developing one of the previously described conditions.
  • prophylactic administration can be applied to avoid the onset of symptoms in a subject diagnosed with the underlying disorder.
  • a combination can be administered to a genetically predisposed subject prior to expected onset of the disease.
  • the amount of a combination that is administered will depend upon a variety of factors, including, for example, the particular condition being treated, the mode of administration, whether the desired benefit is prophylactic or therapeutic, the severity of the condition being treated, the age and weight of the subject, the general health of the subject, and/or the bioavailability of the particular active compound. Determination of an effective dosage is well within the capabilities of those skilled in the art.
  • Dosage, and frequency of administration of the combination will also depend on whether the combination, or separate components thereof, is formulated for treatment of acute episodes of a condition or for the prophylactic treatment of a disorder. A skilled practitioner will be able to determine the optimal dose for a particular individual. Determination of an effective dosage is well within the capabilities of those skilled in the art.
  • Effective dosages can be estimated initially from in vitro activity and metabolism assays.
  • an initial dosage of prodrug for use in animals can be formulated to achieve a circulating blood or serum concentration of the metabolite active compound that is at or above an IC50 of the particular compound as measured in an in vitro assay, such as the in vitro CHMC or BMMC and other in vitro assays described in U.S. application Serial No. 10/355,543 filed January 31, 2003 (US2004/0029902A1), international application Serial No. PCT/US03/03022 filed January 31, 2003 (WO 03/063794), U.S. application Serial No. 10/631,029 filed July 29, 2003, international application Serial No.
  • Initial dosages can also be estimated from in vivo data, such as animal models previously described. Persons of ordinary skill in the art can routinely adapt such information to determine dosages suitable for human administration.
  • Dosage amounts of the JAK inhibitors will typically be in the range of from about 0.0001 or 0.001 or 0.01 mg/kg/day to about 100 mg/kg/day, but can be higher or lower, depending upon, among other factors, the activity of each component of the combination, its bioavailability, the mode of administration, and various factors discussed above. More typically, the dosage (or effective amount) may range from about 5 mg/kg to about 20 mg/kg; even more typically from about 10 mg/kg to about 20 mg/kg; even more typically from about 15 mg/kg to about 20 mg/kg.
  • Typical treatments are from about 1 mg/kg/day to about 20 mg/kg/day, such as from about 1.5 mg/kg/day to about 15 mg/kg/day or from about 2 mg/kg/day to about 10 mg/kg/day.
  • Dosage amount and interval can be adjusted individually to provide plasma levels of each bioactive compound in the combination which are sufficient to maintain therapeutic or prophylactic effect.
  • the combination can be administered once per week, several times per week (e.g., every other day), once per day, or multiple times per day, depending upon, among other things, the mode of administration, the specific indication being treated, and the judgment of the prescribing physician.
  • the effective local concentration of active compounds may not be related to plasma concentration. Skilled artisans will be able to optimize effective local dosages without undue experimentation.
  • the daily dosage of the JAK inhibitor may be greater than zero milligrams per day, such as from about 1 mg/day, up to at least about 2 grams/day.
  • the dosage is about 2 mg/day, about 3 mg/day, about 5 mg/day, about 10 mg/day, about 15 mg/day, about 20 mg/day or about 50 mg/day.
  • the dosage of particular JAK inhibitors is from about 50 mg to about 800 mg/day or from about 250 mg/day to about 1.2 g/day.
  • the JAK inhibitor typically is administered once, twice or three times per day to reach the total daily dosage.
  • the combination will provide therapeutic or prophylactic benefit without causing substantial toxicity. Toxicity of the individual components as well as of the combination, can be determined using standard pharmaceutical procedures.
  • the dose ratio between toxic and therapeutic (or prophylactic) effect is the therapeutic index. Compounds that exhibit high therapeutic indices are preferred in the combination.
  • Particular disclosed embodiments concern a method comprising administering to a subject the disclosed combination in an amount effective to inhibit or prevent a disease, such as a cell proliferative disorder including cancer.
  • the combination may be administered to a subject identified as having cancer or being at risk of developing cancer.
  • administering comprises exposing the subject to a dosage of the combination, or to a dosage of each component of the combination, that is adjusted to inhibit or prevent the disease.
  • the components of a combination also may be administered as multiple pharmaceutical compositions, each comprising one or more components of the combination, or as a single pharmaceutical composition comprising all the components, and typically is administered parenterally (e.g. , intravenously, infusion, or implant), orally, or rectally. Additionally, the combination may be administered prophylactically.
  • the method may further comprise monitoring blood levels of the compound, or a metabolite thereof, in the subject to ascertain the effect of the compound.
  • the method also may further comprise monitoring one or more biomarkers associated with a disease, such as a cancer.
  • the method further comprises monitoring one or more biomarkers associated with a cell proliferative disorder.
  • Suitable biomarkers may include serologic markers such as C-reactive protein, perinuclear antineutrophil cytoplasmic antibody, anti- Saccharomyces cerevisiae antibody, anti-OmpC (outer membrane porin C), anti-I2 protein antibody, anti-glycan antibodies, anti-chitobioside IgA, anti-laminaribioside IgG, anti-manobioside IgG, toll-like receptors 2 and 4, ⁇ -defensin-l, ubiquitination factor E4A (UBE4A), CXCL16 (a chemokine), resistin, apolipoprotein A-IV; genetic biomarkers such as NOD2/CARD 15,
  • fecal biomarkers such as fecal calprotectin and lactoferrin
  • mucosal biomarkers such as mucosal cytokines and chemokines (e.g. , IL-1 , IL- ⁇ , IL-4 IL-6, IL-8, IL- 10, IL-11, IL13Ra2, IL-15, IL- 18, IL-21 , IL-23, IL-32, IFN- ⁇ , TNF-a), monocyte chemotactic protein (MCP)-1 , RANTES, epithelial neutrophil activating protein 78 (ENA-78)), osteoprotegerin, STC1, PTGS2, IL13Ra2, RelA, A20, plgR (polymeric immunoglobulin receptor), GR (glucocorticosteroid receptor) expression, CXCL2, CXCL8, CXCL10, calgranulin B, adhesion molecules and markers of activation (e.g.
  • MAdCAM-1 mucosal vascular addressin CAM-1
  • NF- ⁇ mitogen-activated protein kinase
  • MAPKs e.g. , p38, extracellular signal-regulated kinase and Jun N-terminal kinase
  • immune cells e.g. , IL- 17-positive cells, TH17 cells, Tregs (regulatory T-cells), neutrophils, monocytes, mucosal dendritic cells, macrophages
  • non-immune cells e.g.
  • intestinal epithelial cells with abnormal HLA-DR and/or B7 molecule expression endothelial cells with high expression of CD146, TLR3, TLR4
  • matrix metalloproteinases e.g. , lactate dehydrogenase (LDH) isoenzyme M monomers, LDH 5 monomers, proliferator-activated receptor-2 (PAR2) methylation), mucin 2
  • mucin 2 mean histological inflammation.
  • a method for inhibiting or preventing a disease comprises diagnosing a subject in need of treatment for a disease, or at risk of developing a disease, administering to the subject a combination in an amount effective to inhibit and/or prevent the disease, the combination comprising at least one of the JAK inhibitors disclosed herein and at least one immunooncology agent, and permitting the compounds to achieve therapeutic benefit for the disease in the subject.
  • the disease is a cell proliferative disorder.
  • the method comprises administering one or more disclosed embodiments of the combination to a subject in an amount effective to inhibit or prevent a disease.
  • the combination may comprise at least one compound having any one of formulas I- III, such as any one of the exemplary compounds disclosed in Tables 1 and 3.
  • the disease is a cell proliferative disorder.
  • administering comprises exposing the subject to a first dose of the combination.
  • the method may further comprise determining a therapeutic blood level of the one or more compounds from the combination in the subject, or a therapeutic metabolite blood level of the one or more compounds, in the subject. Additionally, the method may comprise, after determining the therapeutic blood level, adjusting the first dose to a second dose to optimize therapeutic effect.
  • the combination may be administered as a single pharmaceutical composition, or alternatively, the components of the combination may be administered in multiple pharmaceutical compositions, such as two or more compositions. Suitable methods of administration include oral, buccal, mucosal, sublingual, parenteral (e.g.
  • the combination is administered as more than one pharmaceutical composition
  • a person of ordinary skill in the art will appreciate that the various components of the combination may be administered in different ways.
  • a preferred method for administering a JAK inhibitor component of the combination may be different to the preferred method for administering the immunooncological agent, in which case each component may be individually administered by their preferred method.
  • the combination, or at least one component of the combination is administered parenterally, orally, or rectally.
  • the combination may be administered
  • kits for administration of the combination of the JAK inhibitor and the immunooncology agent may comprise pharmaceutical formulations of each individual component of the combination.
  • the pharmaceutical formulations may include a dosage amount of at least one JAK inhibitor or a composition including at least one JAK inhibitor, and at least one immunooncology agent, or a composition including at least one immunooncology agent, as disclosed herein.
  • the kit may include single pharmaceutical compositions that include both the JAK inhibitor(s) and the immunooncology agent(s). Kits can further include suitable packaging and/or instructions for use of the combination.
  • Kits can also include a means for the delivery of each component of the combination, such as an inhaler, spray dispenser (e.g., nasal spray), syringe for injection, or pressure pack for capsules, tables, suppositories, or other device as described herein.
  • a kit can also provide the combination and reagents to prepare a single composition, or separate compositions for each component of the combination, for administration.
  • the composition(s) can be in a dry or lyophilized form or in a solution, particularly a sterile solution.
  • the reagent can include a pharmaceutically acceptable diluent for preparing a liquid formulation.
  • the kit can contain a device for
  • compositions including, but not limited to, syringe, pipette, transdermal patch, or inhalant.
  • kits can include other therapeutic compounds for use in conjunction with the compounds described herein.
  • the therapeutic agents are immunosuppressant or anti-allergen compounds. These compounds can be provided in a separate form or mixed with the presently disclosed combination.
  • kits will include appropriate instructions for preparation and administration of the composition, side effects of the combination, and any other relevant information.
  • the instructions can be in any suitable format, including, but not limited to, printed matter, videotape, computer readable disk or optical disc.
  • kits including a composition comprising a compound of formula I, or a salt, solvate, hydrate, N-oxide or prodrug thereof, an immunooncology agent, packaging, and instructions for use.
  • the kit may include a pharmaceutical formulation including a compound of formula I or a salt, solvate, hydrate, N-oxide or prodrug thereof, and/or a pharmaceutical formulation including an immunooncology agent, and at least one pharmaceutically acceptable excipient, diluent, preservative, stabilizer, or mixture thereof, packaging, and instructions for use for each formulation included.
  • kits for treating an individual who suffers from or is susceptible to a cell proliferative disorder as disclosed herein including a container including a dosage amount of a JAK inhibitor or composition thereof, and an immunooncology agent or composition thereof, as disclosed herein, and instructions for use.
  • the container can be any of those known in the art and appropriate for storage and delivery of oral, intravenous, topical, rectal, urethral, or inhaled formulations.
  • Kits can also be provided that contain sufficient dosages of the combination to provide effective treatment for an individual for an extended period, such as a week, 2 weeks, 3, weeks, 4 weeks, 6 weeks, or 8 weeks or more.
  • a subject in need of treatment for a cell proliferative disorder is selected based on a clinical, diagnostic, and/or histopathological presentation of a cell proliferative disorder.
  • the subject may have symptoms of a cell proliferative disorder.
  • a cell proliferative disorder also may be determined by diagnostic tests and/or procedures, such as blood tests (e.g. , to check for antibodies characteristic of a cell proliferative disorder), stool analysis, colonoscopy, flexible sigmoidoscopy, barium enema, abdominal x-ray, computerized tomography scan, magnetic resonance imaging, capsule endoscopy, and/or double -balloon endoscopy.
  • Subjects also may be selected based on an increased risk of developing a cell proliferative disorder, such as a family history of cell proliferative disorders and/or one or more genetic markers indicating a predisposition toward developing an cell proliferative disorder.
  • the subject is administered a therapeutically effective dose of one or more of the combinations disclosed herein, or pharmaceutical compositions comprising one or more components of the disclosed combination.
  • Administration may be performed via any suitable route including, but not limited to, parenteral (e.g. , intravenous, intraperitoneal, implant), oral, or rectal routes.
  • parenteral e.g. , intravenous, intraperitoneal, implant
  • Treatment may be continued for at least a week, month, or year, and in some subjects treatment may extend over multiple years, the duration of disorder, or the lifetime of the subject.
  • Beneficial or desired results of treatment can include one or more, but are not limited to, alleviation or amelioration of one or more symptoms, diminishment of extent of the cell proliferative disorder, stabilized (i.e., not worsening) state of the subject's condition, delay or slowing of the condition, including disease progression, amelioration or palliation of the condition, and remission (whether partial or total), whether detectable or undetectable.
  • subjects are selected for concomitant treatment with other
  • compositions comprising components of the combination, is administered to the subject with no other treatment for the cell proliferative disorder.

Abstract

Selon des modes de réalisation décrits, l'invention concerne une combinaison comprenant un inhibiteur de JAK et un agent immuno-oncologique. L'agent immuno-oncologique peut comprendre un anticorps anti-PD-1, un anticorps anti-PD-L1, un inhibiteur de PI3K, un inhibiteur d'indole dioxygénase ou une combinaison de ceux-ci. L'inhibiteur de JAK peut être une pyrimidin-2-amine, une 2,4-pyrimidinediamine, ou une combinaison de celles-ci. Des modes de réalisation d'une méthode destinée à utiliser ladite combinaison pour traiter un sujet, en particulier un sujet présentant un trouble de type prolifération cellulaire sont en outre décrits. La méthode peut en outre comprendre l'administration d'un ou de plusieurs agents thérapeutiques en plus de l'inhibiteur de JAK et de l'agent immuno-oncologique. Des kits comprenant ladite combinaison sont en outre décrits.
PCT/US2016/040151 2015-07-07 2016-06-29 Combinaison à médiation immunitaire pour le traitement du cancer WO2017007658A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189524P 2015-07-07 2015-07-07
US62/189,524 2015-07-07

Publications (1)

Publication Number Publication Date
WO2017007658A1 true WO2017007658A1 (fr) 2017-01-12

Family

ID=56413886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/040151 WO2017007658A1 (fr) 2015-07-07 2016-06-29 Combinaison à médiation immunitaire pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2017007658A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107827875A (zh) * 2017-09-25 2018-03-23 文韬创新药物研究（北京）有限责任公司 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用
CN108623591A (zh) * 2017-03-24 2018-10-09 中国海洋大学 一种哌尼诺安化合物的用途
CN109876000A (zh) * 2018-05-29 2019-06-14 上海交通大学医学院附属第九人民医院 帕布昔利布在黏膜恶性黑色素瘤中的应用
WO2019224141A1 (fr) * 2018-05-24 2019-11-28 Astrazeneca Ab Sel de fumarate de 5-((5-méthyl-2-((3,4,5-triméthylphényl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3h)-one
WO2020044206A1 (fr) * 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques utiles en tant qu'inhibiteurs de kinases destinés à être utilisés dans le traitement du cancer
CN111163839A (zh) * 2017-05-26 2020-05-15 癌症研究科技有限公司 苯并咪唑酮衍生的bcl6抑制剂
CN112142675A (zh) * 2020-10-09 2020-12-29 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
CN112888441A (zh) * 2018-08-14 2021-06-01 梅制药公司 B细胞恶性肿瘤的治疗
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN113880813A (zh) * 2020-07-01 2022-01-04 杭州百诚医药科技股份有限公司 一种2-氨基嘧啶类杂环化合物及应用
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2022171121A1 (fr) * 2021-02-10 2022-08-18 同润生物医药(上海)有限公司 Méthode et combinaison pour le traitement de tumeurs
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2023017937A1 (fr) * 2021-08-10 2023-02-16 계명대학교 산학협력단 Nouvel inhibiteur pour de multiples protéines kinases
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085684A1 (fr) * 2009-01-23 2010-07-29 Rigel Pharmaceuticals, Inc. Compositions et procédés pour l'inhibition de la voie jak
WO2012015972A1 (fr) * 2010-07-28 2012-02-02 Rigel Pharmaceuticals, Inc. Compositions et procédés d'inhibition de la voie jak
US20140213585A1 (en) * 2008-02-15 2014-07-31 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
WO2015051252A1 (fr) * 2013-10-03 2015-04-09 Duke University Compositions et méthodes destinées à traiter les cancers ayant une activité jak2
WO2016024228A1 (fr) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques associant un inhibiteur de btk, un inhibiteur de pi3k, un inhibiteur de jak-2, un inhibiteur de pd-1 et/ou un inhibiteur de pd-l1
WO2016054555A2 (fr) * 2014-10-03 2016-04-07 Novartis Ag Polythérapies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140213585A1 (en) * 2008-02-15 2014-07-31 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
WO2010085684A1 (fr) * 2009-01-23 2010-07-29 Rigel Pharmaceuticals, Inc. Compositions et procédés pour l'inhibition de la voie jak
WO2012015972A1 (fr) * 2010-07-28 2012-02-02 Rigel Pharmaceuticals, Inc. Compositions et procédés d'inhibition de la voie jak
WO2015051252A1 (fr) * 2013-10-03 2015-04-09 Duke University Compositions et méthodes destinées à traiter les cancers ayant une activité jak2
WO2016024228A1 (fr) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Combinaisons thérapeutiques associant un inhibiteur de btk, un inhibiteur de pi3k, un inhibiteur de jak-2, un inhibiteur de pd-1 et/ou un inhibiteur de pd-l1
WO2016054555A2 (fr) * 2014-10-03 2016-04-07 Novartis Ag Polythérapies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
G. K. PHILIPS ET AL: "Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies", INTERNATIONAL IMMUNOLOGY., vol. 27, no. 1, 16 October 2014 (2014-10-16), GB, pages 39 - 46, XP055217958, ISSN: 0953-8178, DOI: 10.1093/intimm/dxu095 *
K. SHIDE ET AL: "R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm", BLOOD, vol. 117, no. 25, 23 June 2011 (2011-06-23), pages 6866 - 6875, XP055066326, ISSN: 0006-4971, DOI: 10.1182/blood-2010-01-262535 *
M. R. GREEN ET AL: "Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma", BLOOD, vol. 116, no. 17, 28 October 2010 (2010-10-28), US, pages 3268 - 3277, XP055305384, ISSN: 0006-4971, DOI: 10.1182/blood-2010-05-282780 *
MENG LING CHOONG ET AL: "Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms", 54TH ASH ANNUAL MEETING AND EXPOSITION; 8-11 DECEMBER, 2012; ATLANTA, GA; ABSTRACTS, PROGRAM, AND PERSONAL SCHEDULER,, 9 December 2012 (2012-12-09), pages 1, XP002736664, Retrieved from the Internet <URL:https://ash.confex.com/ash/2012/webprogram/Paper47518.html> *
ROBERTO BELLUCCI ET AL: "Interferon-[gamma]-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression", ONCOIMMUNOLOGY, vol. 4, no. 6, 3 June 2015 (2015-06-03), US, pages e1008824, XP055305374, ISSN: 2162-4011, DOI: 10.1080/2162402X.2015.1008824 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623591A (zh) * 2017-03-24 2018-10-09 中国海洋大学 一种哌尼诺安化合物的用途
CN108623591B (zh) * 2017-03-24 2021-08-17 中国海洋大学 一种哌尼诺安化合物的用途
JP7202315B2 (ja) 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
CN111163839A (zh) * 2017-05-26 2020-05-15 癌症研究科技有限公司 苯并咪唑酮衍生的bcl6抑制剂
JP2020521771A (ja) * 2017-05-26 2020-07-27 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ ベンズイミダゾロン由来のｂｃｌ６阻害剤
CN107827875B (zh) * 2017-09-25 2021-07-09 文韬创新药物研究（北京）有限责任公司 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用
CN107827875A (zh) * 2017-09-25 2018-03-23 文韬创新药物研究（北京）有限责任公司 一种苯并咪唑类衍生物作为周期蛋白依赖性激酶4/6抑制剂的应用
CN112154148A (zh) * 2018-05-24 2020-12-29 阿斯利康(瑞典)有限公司 5-((5-甲基-2-((3,4,5-三甲基苯基)氨基)嘧啶-4-基)氨基)-苯并[d]噁唑-2(3H)-酮的富马酸盐
AU2019272703B8 (en) * 2018-05-24 2022-05-26 Rigel Pharmaceuticals, Inc. Fumarate salt of 5-((5-methyl-2-((3,4,5-trimethylphenyl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3H)-one
JP2021524458A (ja) * 2018-05-24 2021-09-13 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ ５−（（５−メチル−２−（（３，４，５−トリメチルフェニル）アミノ）ピリミジン−４−イル）アミノ）−ベンゾ［ｄ］オキサゾール−２（３Ｈ）−オンのフマル酸塩
WO2019224141A1 (fr) * 2018-05-24 2019-11-28 Astrazeneca Ab Sel de fumarate de 5-((5-méthyl-2-((3,4,5-triméthylphényl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3h)-one
AU2019272703B2 (en) * 2018-05-24 2022-05-12 Rigel Pharmaceuticals, Inc. Fumarate salt of 5-((5-methyl-2-((3,4,5-trimethylphenyl)amino)pyrimidin-4-yl)amino)-benzo[d]oxazol-2(3H)-one
CN109876000A (zh) * 2018-05-29 2019-06-14 上海交通大学医学院附属第九人民医院 帕布昔利布在黏膜恶性黑色素瘤中的应用
CN112888441A (zh) * 2018-08-14 2021-06-01 梅制药公司 B细胞恶性肿瘤的治疗
WO2020044206A1 (fr) * 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Amides hétérocycliques utiles en tant qu'inhibiteurs de kinases destinés à être utilisés dans le traitement du cancer
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN113880813A (zh) * 2020-07-01 2022-01-04 杭州百诚医药科技股份有限公司 一种2-氨基嘧啶类杂环化合物及应用
CN112142675B (zh) * 2020-10-09 2021-11-30 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
WO2022073424A1 (fr) * 2020-10-09 2022-04-14 嘉兴特科罗生物科技有限公司 Composé à petites molécules servant d'inhibiteur de kinase jak et son utilisation
CN112142675A (zh) * 2020-10-09 2020-12-29 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
WO2022171121A1 (fr) * 2021-02-10 2022-08-18 同润生物医药(上海)有限公司 Méthode et combinaison pour le traitement de tumeurs
WO2023017937A1 (fr) * 2021-08-10 2023-02-16 계명대학교 산학협력단 Nouvel inhibiteur pour de multiples protéines kinases
KR20230023206A (ko) * 2021-08-10 2023-02-17 계명대학교 산학협력단 신규한 다중 단백질 키나아제 억제제
KR102566028B1 (ko) 2021-08-10 2023-08-10 계명대학교 산학협력단 신규한 다중 단백질 키나아제 억제제

Similar Documents

Publication Publication Date Title
WO2017007658A1 (fr) Combinaison à médiation immunitaire pour le traitement du cancer
AU2020204418B2 (en) Benzoxazepin oxazolidinone compounds and methods of use
US10966963B2 (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
US11673902B2 (en) Isoindolinone and indazole compounds for the degradation of EGFR
JP6695353B2 (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
UA119537C2 (uk) ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
US20220363696A1 (en) Amino-substituted heterocycles for treating cancers with egfr mutations
US11529350B2 (en) Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
JP2023538520A (ja) Ｉｋａｒｏｓ又はａｉｏｌｏｓによって媒介される障害に対する有利な治療法
JP2023528257A (ja) 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
CA2899281C (fr) Composes de pyrimidinediamines pour utilisation dans le traitement ou laprevention de l&#39;alopecie auto-immune
JP2024511801A (ja) （フロピリミジン－４－イル）ピペラジン化合物及びその使用
CN117440813A (zh) 治疗脑或cns的癌转移的egfr降解剂
WO2020206034A1 (fr) Composés d&#39;inhibition de cycle cellulaire pour le traitement de troubles médicaux
BR112017023121B1 (pt) Composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, kit para o tratamento terapêutico do câncer, e uso de um composto

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16739340

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16739340

Country of ref document: EP

Kind code of ref document: A1